CA3118005C - Aerosolisable formulation - Google Patents
Aerosolisable formulation Download PDFInfo
- Publication number
- CA3118005C CA3118005C CA3118005A CA3118005A CA3118005C CA 3118005 C CA3118005 C CA 3118005C CA 3118005 A CA3118005 A CA 3118005A CA 3118005 A CA3118005 A CA 3118005A CA 3118005 C CA3118005 C CA 3118005C
- Authority
- CA
- Canada
- Prior art keywords
- formulation
- nicotine
- aerosolisable
- acid
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 502
- 238000009472 formulation Methods 0.000 title claims abstract description 466
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims abstract description 232
- 229960002715 nicotine Drugs 0.000 claims abstract description 213
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims abstract description 213
- 239000002253 acid Substances 0.000 claims abstract description 193
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 124
- 229920000858 Cyclodextrin Polymers 0.000 claims description 74
- 239000000443 aerosol Substances 0.000 claims description 55
- 229940097362 cyclodextrins Drugs 0.000 claims description 47
- 238000000034 method Methods 0.000 claims description 41
- 239000000796 flavoring agent Substances 0.000 claims description 31
- 235000019634 flavors Nutrition 0.000 claims description 30
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 21
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 21
- 150000007513 acids Chemical class 0.000 claims description 17
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 16
- 239000005711 Benzoic acid Substances 0.000 claims description 8
- 235000010233 benzoic acid Nutrition 0.000 claims description 8
- 235000011054 acetic acid Nutrition 0.000 claims description 7
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 7
- 239000004334 sorbic acid Substances 0.000 claims description 7
- 235000010199 sorbic acid Nutrition 0.000 claims description 7
- 229940075582 sorbic acid Drugs 0.000 claims description 7
- JOOXCMJARBKPKM-UHFFFAOYSA-N 4-oxopentanoic acid Chemical compound CC(=O)CCC(O)=O JOOXCMJARBKPKM-UHFFFAOYSA-N 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 229940041616 menthol Drugs 0.000 claims description 6
- 230000001953 sensory effect Effects 0.000 claims description 6
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 5
- -1 y-undecalactone Chemical compound 0.000 claims description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 3
- 150000001735 carboxylic acids Chemical class 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 229940040102 levulinic acid Drugs 0.000 claims description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 3
- 239000011976 maleic acid Substances 0.000 claims description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 claims description 2
- RADIRXJQODWKGQ-HWKANZROSA-N 2-Ethoxy-5-(1-propenyl)phenol Chemical compound CCOC1=CC=C(\C=C\C)C=C1O RADIRXJQODWKGQ-HWKANZROSA-N 0.000 claims description 2
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 claims description 2
- 229930007503 menthone Natural products 0.000 claims description 2
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 claims description 2
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 claims description 2
- 235000012141 vanillin Nutrition 0.000 claims description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims 2
- 244000126002 Ziziphus vulgaris Species 0.000 claims 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 99
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 99
- 238000012360 testing method Methods 0.000 description 19
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 12
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 12
- 229940035437 1,3-propanediol Drugs 0.000 description 12
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 12
- 239000003571 electronic cigarette Substances 0.000 description 10
- 239000002245 particle Substances 0.000 description 9
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 6
- 241000222122 Candida albicans Species 0.000 description 5
- 229940095731 candida albicans Drugs 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 235000019504 cigarettes Nutrition 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 4
- 231100000167 toxic agent Toxicity 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- 241000228212 Aspergillus Species 0.000 description 3
- 241000589516 Pseudomonas Species 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- 241000191940 Staphylococcus Species 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 235000012550 Pimpinella anisum Nutrition 0.000 description 2
- 240000004760 Pimpinella anisum Species 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000000779 smoke Substances 0.000 description 2
- 235000019614 sour taste Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 235000019505 tobacco product Nutrition 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- HOSGXJWQVBHGLT-UHFFFAOYSA-N 6-hydroxy-3,4-dihydro-1h-quinolin-2-one Chemical group N1C(=O)CCC2=CC(O)=CC=C21 HOSGXJWQVBHGLT-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 240000007087 Apium graveolens Species 0.000 description 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 1
- 235000010591 Appio Nutrition 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241001331781 Aspergillus brasiliensis Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 240000007436 Cananga odorata Species 0.000 description 1
- 235000005747 Carum carvi Nutrition 0.000 description 1
- 240000000467 Carum carvi Species 0.000 description 1
- 240000003538 Chamaemelum nobile Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 240000007154 Coffea arabica Species 0.000 description 1
- 235000002787 Coriandrum sativum Nutrition 0.000 description 1
- 244000018436 Coriandrum sativum Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 240000002943 Elettaria cardamomum Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 240000006927 Foeniculum vulgare Species 0.000 description 1
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 240000001238 Gaultheria procumbens Species 0.000 description 1
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 1
- 241000208152 Geranium Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 244000267823 Hydrangea macrophylla Species 0.000 description 1
- 235000014486 Hydrangea macrophylla Nutrition 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- 240000005385 Jasminum sambac Species 0.000 description 1
- 244000255365 Kaskarillabaum Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 244000165082 Lavanda vera Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- 241000768444 Magnolia obovata Species 0.000 description 1
- 235000011430 Malus pumila Nutrition 0.000 description 1
- 235000015103 Malus silvestris Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 235000014435 Mentha Nutrition 0.000 description 1
- 241001072983 Mentha Species 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000016278 Mentha canadensis Nutrition 0.000 description 1
- 244000245214 Mentha canadensis Species 0.000 description 1
- 235000014749 Mentha crispa Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 244000078639 Mentha spicata Species 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 244000179970 Monarda didyma Species 0.000 description 1
- 235000010672 Monarda didyma Nutrition 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- 244000270834 Myristica fragrans Species 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 240000000513 Santalum album Species 0.000 description 1
- 235000008632 Santalum album Nutrition 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 235000001484 Trigonella foenum graecum Nutrition 0.000 description 1
- 244000250129 Trigonella foenum graecum Species 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000005300 cardamomo Nutrition 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 235000020057 cognac Nutrition 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical class OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000001702 nutmeg Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 238000003921 particle size analysis Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 235000019719 rose oil Nutrition 0.000 description 1
- 239000010666 rose oil Substances 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-N sorbic acid group Chemical group C(\C=C\C=C\C)(=O)O WSWCOQWTEOXDQX-MQQKCMAXSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000013179 statistical model Methods 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 235000021092 sugar substitutes Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 235000001019 trigonella foenum-graecum Nutrition 0.000 description 1
- 235000015041 whisky Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/10—Chemical features of tobacco products or tobacco substitutes
- A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
- A24B15/167—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes in liquid or vaporisable form, e.g. liquid compositions for electronic cigarettes
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/18—Treatment of tobacco products or tobacco substitutes
- A24B15/24—Treatment of tobacco products or tobacco substitutes by extraction; Tobacco extracts
- A24B15/241—Extraction of specific substances
- A24B15/243—Nicotine
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/18—Treatment of tobacco products or tobacco substitutes
- A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
- A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
- A24F40/10—Devices using liquid inhalable precursors
Abstract
There is provided an aerosolisable formulation comprising (i) water in an amount of at least 20 wt.% based on the aerosolisable formulation; (ii) nicotine; and (iii) an acid which is at least partially water soluble; wherein at least 5 wt% of the nicotine present in the formulation is in protonated form; and wherein the formulation has a pH of from 4 to 6.
Description
AEROSOLISABLE FORMULATION
FIELD OF THE INVENTION
The present disclosure relates to an aerosolisable formulation, a method of forming the same, a container containing the same, a device containing the same and processes and uses of the same.
BACKGROUND TO THE INVENTION
Electronic aerosol provision systems such as e-cigarettes generally contain a reservoir of liquid which is to be vaporised, typically containing nicotine. When a user inhales on the device, a heater is activated to vaporise a small amount of liquid, which is therefore inhaled by the user.
The use of e-cigarettes in the UK has grown rapidly, and it has been estimated that there are now over a million people using them in the UK.
One challenge faced in providing such systems is to provide from the aerosol provision device an aerosol to be inhaled which provides consumers with an acceptable experience.
Some consumers may prefer an e-cigarette that generates an aerosol that closely 'mimics' smoke inhaled from a tobacco product such as a cigarette. Aerosols from e-cigarettes and smoke from tobacco products such as cigarettes provides to the user a complex chain of flavour in the mouth, nicotine absorption in the mouth and throat, followed by nicotine .. absorption in the lungs. These various aspects are described by users in terms of flavour, intensity/quality, impact, irritation/smoothness and nicotine reward. Nicotine contributes to a number of these factors, and is strongly associated with factors such as impact, irritation and smoothness; these are readily perceived by consumers, and e-cigarettes may offer too much or too little of these parameters for consumers, depending upon individual preferences.
Nicotine reward is particularly complex as it results from both the amount of and speed with which nicotine is absorbed from the lining of the mouth, this is typically nicotine in the vapour phase, and from the amount and speed nicotine that is absorbed from the lungs, this is typically nicotine in the particulate phase of the aerosol which is inhaled.
Each of these factors, and their balance, can strongly contribute to consumer acceptability of an e-.. cigarette. Providing means to optimise the overall vaping experience is therefore desirable to e-cigarette manufacturers.
A further challenge facing such systems is the continued demand for harm reduction. Harm from cigarette and e-cigarette devices primarily comes from toxicants.
Therefore, there is a desire to reduce the components present in the system which may form toxicants.
SUMMARY OF THE INVENTION
In one aspect there is provided an aerosolisable formulation comprising (i) water in an amount of at least 20 wt.% based on the aerosolisable formulation;
(ii) nicotine; and (iii) an acid which is at least partially water soluble;
wherein at least 5 wt% of the nicotine present in the formulation is in protonated form; and wherein the formulation has a pH of from 4 to 6.
In one aspect there is provided a process for forming an aerosol, the process comprising aerosolising an aerosolisable formulation comprising (i) water in an amount of at least 20 wt.% based on the aerosolisable formulation;
(ii) nicotine; and (iii) an acid which is at least partially water soluble;
wherein at least 5 wt% of the nicotine present in the formulation is in protonated form; and wherein the formulation has a pH of from 4 to 6.
In one aspect there is provided a contained aerosolisable formulation comprising (a) a container; and (b) an aerosolisable formulation, comprising (i) water in an amount of at least 20 wt.% based on the aerosolisable formulation;
(ii) nicotine; and (iii) an acid which is at least partially water soluble;
wherein at least 5 wt% of the nicotine present in the formulation is in protonated form;
and wherein the formulation has a pH of from 4 to 6.
In one aspect there is provided an electronic aerosol provision system comprising:
(a) an aerosoliser for aerosolising formulation for inhalation by a user of the electronic aerosol provision system;
(b) a power supply comprising a cell or battery for supplying power to the aerosoliser (c) an aerosolisable formulation , comprising (i) water in an amount of at least 20 wt.% based on the aerosolisable formulation;
FIELD OF THE INVENTION
The present disclosure relates to an aerosolisable formulation, a method of forming the same, a container containing the same, a device containing the same and processes and uses of the same.
BACKGROUND TO THE INVENTION
Electronic aerosol provision systems such as e-cigarettes generally contain a reservoir of liquid which is to be vaporised, typically containing nicotine. When a user inhales on the device, a heater is activated to vaporise a small amount of liquid, which is therefore inhaled by the user.
The use of e-cigarettes in the UK has grown rapidly, and it has been estimated that there are now over a million people using them in the UK.
One challenge faced in providing such systems is to provide from the aerosol provision device an aerosol to be inhaled which provides consumers with an acceptable experience.
Some consumers may prefer an e-cigarette that generates an aerosol that closely 'mimics' smoke inhaled from a tobacco product such as a cigarette. Aerosols from e-cigarettes and smoke from tobacco products such as cigarettes provides to the user a complex chain of flavour in the mouth, nicotine absorption in the mouth and throat, followed by nicotine .. absorption in the lungs. These various aspects are described by users in terms of flavour, intensity/quality, impact, irritation/smoothness and nicotine reward. Nicotine contributes to a number of these factors, and is strongly associated with factors such as impact, irritation and smoothness; these are readily perceived by consumers, and e-cigarettes may offer too much or too little of these parameters for consumers, depending upon individual preferences.
Nicotine reward is particularly complex as it results from both the amount of and speed with which nicotine is absorbed from the lining of the mouth, this is typically nicotine in the vapour phase, and from the amount and speed nicotine that is absorbed from the lungs, this is typically nicotine in the particulate phase of the aerosol which is inhaled.
Each of these factors, and their balance, can strongly contribute to consumer acceptability of an e-.. cigarette. Providing means to optimise the overall vaping experience is therefore desirable to e-cigarette manufacturers.
A further challenge facing such systems is the continued demand for harm reduction. Harm from cigarette and e-cigarette devices primarily comes from toxicants.
Therefore, there is a desire to reduce the components present in the system which may form toxicants.
SUMMARY OF THE INVENTION
In one aspect there is provided an aerosolisable formulation comprising (i) water in an amount of at least 20 wt.% based on the aerosolisable formulation;
(ii) nicotine; and (iii) an acid which is at least partially water soluble;
wherein at least 5 wt% of the nicotine present in the formulation is in protonated form; and wherein the formulation has a pH of from 4 to 6.
In one aspect there is provided a process for forming an aerosol, the process comprising aerosolising an aerosolisable formulation comprising (i) water in an amount of at least 20 wt.% based on the aerosolisable formulation;
(ii) nicotine; and (iii) an acid which is at least partially water soluble;
wherein at least 5 wt% of the nicotine present in the formulation is in protonated form; and wherein the formulation has a pH of from 4 to 6.
In one aspect there is provided a contained aerosolisable formulation comprising (a) a container; and (b) an aerosolisable formulation, comprising (i) water in an amount of at least 20 wt.% based on the aerosolisable formulation;
(ii) nicotine; and (iii) an acid which is at least partially water soluble;
wherein at least 5 wt% of the nicotine present in the formulation is in protonated form;
and wherein the formulation has a pH of from 4 to 6.
In one aspect there is provided an electronic aerosol provision system comprising:
(a) an aerosoliser for aerosolising formulation for inhalation by a user of the electronic aerosol provision system;
(b) a power supply comprising a cell or battery for supplying power to the aerosoliser (c) an aerosolisable formulation , comprising (i) water in an amount of at least 20 wt.% based on the aerosolisable formulation;
2
3 (ii) nicotine; and (iii) an acid which is at least partially water soluble;
wherein at least 5 wt% of the nicotine present in the formulation is in protonated form;
and wherein the formulation has a pH of from 4 to 6.
In one aspect there is provided a process for improving the sensory properties of an aerosolised nicotine formulation, the process comprising the steps of (a) providing an aerosolisable material comprising (i) water in an amount of at least 20 wt%
based on the aerosolisable material and (ii) nicotine;
(b) incorporating into the aerosolisable material an acid which is at least partially water soluble;
wherein at least 5 wt% of the nicotine present in the formulation is in protonated form; and wherein the formulation has a pH of from 4 to 6.
In one aspect there is provided a process for improving the storage stability of an aerosolised nicotine formulation, the process comprising the steps of (a) providing an aerosolisable material comprising (i) water in an amount of at least 20 wt%
based on the aerosolisable material and (ii) nicotine;
(b) incorporating into the aerosolisable material an acid which is at least partially water soluble;
wherein at least 5 wt% of the nicotine present in the formulation is in protonated form; and wherein the formulation has a pH of from 4 to 6.
In one aspect there is provided use of one or more acids for improving sensory properties of an aerosolised nicotine formulation, wherein the nicotine formulation comprises (i) water in an amount of at least 20 wt.% based on the aerosolisable formulation;
(ii) nicotine; and (iii) an acid which is at least partially water soluble;
wherein at least 5 wt% of the nicotine present in the formulation is in protonated form;
and wherein the formulation has a pH of from 4 to 6.
In one aspect there is provided use of one or more acids for improving storage stability of an aerosolised nicotine formulation, wherein the nicotine formulation comprises (i) water in an amount of at least 20 wt.% based on the aerosolisable formulation;
(ii) nicotine; and (iii) an acid which is at least partially water soluble;
wherein at least 5 wt% of the nicotine present in the formulation is in protonated form; and wherein the formulation has a pH of from 4 to 6.
DETAILED DESCRIPTION
As discussed herein in one aspect there is provided an aerosolisable formulation comprising (i) water in an amount of at least 20 wt.% based on the aerosolisable formulation;
(ii) nicotine; and (iii) an acid which is at least partially water soluble;
wherein at least 5 wt% of the nicotine present in the formulation is in protonated form; and wherein the formulation has a pH of from 4 to 6.
We have found that an advantageous system may be provided which contains water and in which an acid which is at least partially dissolved. In particular the inclusion of the an acid such that at least 5 wt% of the nicotine present in the formulation is in protonated form and such that the formulation has a pH of from 4 to 6 both protonates the nicotine and inhibits microbial growth in the water containing system. In such a system, the number of components present may be reduced leading to less chance of forming breakdown products/toxicants. In particular, the use of water allows for the replacement of some or all of the glycerol, propylene glycol, 1,3-propane diol and mixtures thereof typically used in e-cigarettes. Furthermore, the use of an acid as a multi-functional component also allows for a reduction in the number of components in the formulation.
As is understood by one skilled in the art, nicotine may exist in unprotonated form, monoprotonated form or diprotonated form. The structures of each of these forms are given below.
H H H
N ,,,,N
1 \ 1 H/ r,1_, \
.-0. .3 1 Fi" \CH3 CH3 i\l+
N
N
I
H
Unprotonated nicotine monoprotonated nicotine di protonated nicotine Reference in the specification to protonated form means both monoprotonated nicotine and diprotonated nicotine. Reference in the specification to amounts in the protonated form
wherein at least 5 wt% of the nicotine present in the formulation is in protonated form;
and wherein the formulation has a pH of from 4 to 6.
In one aspect there is provided a process for improving the sensory properties of an aerosolised nicotine formulation, the process comprising the steps of (a) providing an aerosolisable material comprising (i) water in an amount of at least 20 wt%
based on the aerosolisable material and (ii) nicotine;
(b) incorporating into the aerosolisable material an acid which is at least partially water soluble;
wherein at least 5 wt% of the nicotine present in the formulation is in protonated form; and wherein the formulation has a pH of from 4 to 6.
In one aspect there is provided a process for improving the storage stability of an aerosolised nicotine formulation, the process comprising the steps of (a) providing an aerosolisable material comprising (i) water in an amount of at least 20 wt%
based on the aerosolisable material and (ii) nicotine;
(b) incorporating into the aerosolisable material an acid which is at least partially water soluble;
wherein at least 5 wt% of the nicotine present in the formulation is in protonated form; and wherein the formulation has a pH of from 4 to 6.
In one aspect there is provided use of one or more acids for improving sensory properties of an aerosolised nicotine formulation, wherein the nicotine formulation comprises (i) water in an amount of at least 20 wt.% based on the aerosolisable formulation;
(ii) nicotine; and (iii) an acid which is at least partially water soluble;
wherein at least 5 wt% of the nicotine present in the formulation is in protonated form;
and wherein the formulation has a pH of from 4 to 6.
In one aspect there is provided use of one or more acids for improving storage stability of an aerosolised nicotine formulation, wherein the nicotine formulation comprises (i) water in an amount of at least 20 wt.% based on the aerosolisable formulation;
(ii) nicotine; and (iii) an acid which is at least partially water soluble;
wherein at least 5 wt% of the nicotine present in the formulation is in protonated form; and wherein the formulation has a pH of from 4 to 6.
DETAILED DESCRIPTION
As discussed herein in one aspect there is provided an aerosolisable formulation comprising (i) water in an amount of at least 20 wt.% based on the aerosolisable formulation;
(ii) nicotine; and (iii) an acid which is at least partially water soluble;
wherein at least 5 wt% of the nicotine present in the formulation is in protonated form; and wherein the formulation has a pH of from 4 to 6.
We have found that an advantageous system may be provided which contains water and in which an acid which is at least partially dissolved. In particular the inclusion of the an acid such that at least 5 wt% of the nicotine present in the formulation is in protonated form and such that the formulation has a pH of from 4 to 6 both protonates the nicotine and inhibits microbial growth in the water containing system. In such a system, the number of components present may be reduced leading to less chance of forming breakdown products/toxicants. In particular, the use of water allows for the replacement of some or all of the glycerol, propylene glycol, 1,3-propane diol and mixtures thereof typically used in e-cigarettes. Furthermore, the use of an acid as a multi-functional component also allows for a reduction in the number of components in the formulation.
As is understood by one skilled in the art, nicotine may exist in unprotonated form, monoprotonated form or diprotonated form. The structures of each of these forms are given below.
H H H
N ,,,,N
1 \ 1 H/ r,1_, \
.-0. .3 1 Fi" \CH3 CH3 i\l+
N
N
I
H
Unprotonated nicotine monoprotonated nicotine di protonated nicotine Reference in the specification to protonated form means both monoprotonated nicotine and diprotonated nicotine. Reference in the specification to amounts in the protonated form
4 means the combined amount of monoprotonated nicotine and diprotonated nicotine.
Furthermore, when reference is made to a fully protonated formulation it will be understood that at any one time there may be very minor amounts of unprotonated nicotine present, e.g.
less than 1% unprotonated.
For ease of reference, these and further aspects of the present invention are now discussed under appropriate section headings. However, the teachings under each section are not necessarily limited to each particular section.
Water As discussed herein the aerosolisable formulation comprises water in an amount of at least wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 25 wt.% based on the aerosolisable formulation. In one aspect water is present in 15 an amount of at least 30 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 35 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 40 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 45 wt.%
based on the aerosolisable formulation. In one aspect water is present in an amount of at least 50 wt.%
20 based on the aerosolisable formulation. In one aspect water is present in an amount of at least 55 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 60 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 65 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 70 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 75 wt.%
based on the aerosolisable formulation. In one aspect water is present in an amount of at least 80 wt.%
based on the aerosolisable formulation. In one aspect water is present in an amount of at least 85 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 90 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 95 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 99 wt.% based on the aerosolisable formulation.
In one aspect water is present in an amount of from 20 to 99 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of from 25 to 99 wt.%
based on the aerosolisable formulation. In one aspect water is present in an amount of from 30 to 99 wt.% based on the aerosolisable formulation. In one aspect water is present in an
Furthermore, when reference is made to a fully protonated formulation it will be understood that at any one time there may be very minor amounts of unprotonated nicotine present, e.g.
less than 1% unprotonated.
For ease of reference, these and further aspects of the present invention are now discussed under appropriate section headings. However, the teachings under each section are not necessarily limited to each particular section.
Water As discussed herein the aerosolisable formulation comprises water in an amount of at least wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 25 wt.% based on the aerosolisable formulation. In one aspect water is present in 15 an amount of at least 30 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 35 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 40 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 45 wt.%
based on the aerosolisable formulation. In one aspect water is present in an amount of at least 50 wt.%
20 based on the aerosolisable formulation. In one aspect water is present in an amount of at least 55 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 60 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 65 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 70 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 75 wt.%
based on the aerosolisable formulation. In one aspect water is present in an amount of at least 80 wt.%
based on the aerosolisable formulation. In one aspect water is present in an amount of at least 85 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 90 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 95 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 99 wt.% based on the aerosolisable formulation.
In one aspect water is present in an amount of from 20 to 99 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of from 25 to 99 wt.%
based on the aerosolisable formulation. In one aspect water is present in an amount of from 30 to 99 wt.% based on the aerosolisable formulation. In one aspect water is present in an
5 amount of from 35 to 99 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of from 40 to 99 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of from 45 to 99 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of from 50 to 99 wt.%
based on the aerosolisable formulation. In one aspect water is present in an amount of from 55 to 99 wt.%
based on the aerosolisable formulation. In one aspect water is present in an amount of from 60 to 99 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of from 65 to 99 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of from 70 to 99 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of from 75 to 99 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of from 80 to 99 wt.%
based on the aerosolisable formulation. In one aspect water is present in an amount of from 85 to 99 wt %
based on the aerosolisable formulation. In one aspect water is present in an amount of from 90 to 99 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of from 95 to 99 wt.% based on the aerosolisable formulation.
As discussed herein the use of water allows for the replacement of some or all of the glycerol, propylene glycol, 1,3-propane diol and mixtures thereof typically used in e-cigarettes. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, 1,3-propane diol and mixtures thereof in a combined amount of no greater than 10 wt.%
based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, 1,3-propane diol and mixtures thereof in a combined amount of no greater than 8 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, 1,3-propane diol and mixtures thereof in a combined amount of no greater than 5 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, 1,3-propane diol and mixtures thereof in a combined amount of no greater than 2 wt.%
based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, 1,3-propane diol and mixtures thereof in a combined amount of no greater than 1 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, 1,3-propane diol and mixtures thereof in a combined amount of no greater than 0.5 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, 1,3-propane diol and mixtures thereof in a combined amount of no greater than 0.2 wt.%
based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, 1,3-propane diol and mixtures thereof in a combined amount of no greater than 0.1 wt.% based on the aerosolisable formulation. In one aspect the
based on the aerosolisable formulation. In one aspect water is present in an amount of from 55 to 99 wt.%
based on the aerosolisable formulation. In one aspect water is present in an amount of from 60 to 99 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of from 65 to 99 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of from 70 to 99 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of from 75 to 99 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of from 80 to 99 wt.%
based on the aerosolisable formulation. In one aspect water is present in an amount of from 85 to 99 wt %
based on the aerosolisable formulation. In one aspect water is present in an amount of from 90 to 99 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of from 95 to 99 wt.% based on the aerosolisable formulation.
As discussed herein the use of water allows for the replacement of some or all of the glycerol, propylene glycol, 1,3-propane diol and mixtures thereof typically used in e-cigarettes. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, 1,3-propane diol and mixtures thereof in a combined amount of no greater than 10 wt.%
based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, 1,3-propane diol and mixtures thereof in a combined amount of no greater than 8 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, 1,3-propane diol and mixtures thereof in a combined amount of no greater than 5 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, 1,3-propane diol and mixtures thereof in a combined amount of no greater than 2 wt.%
based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, 1,3-propane diol and mixtures thereof in a combined amount of no greater than 1 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, 1,3-propane diol and mixtures thereof in a combined amount of no greater than 0.5 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, 1,3-propane diol and mixtures thereof in a combined amount of no greater than 0.2 wt.%
based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, 1,3-propane diol and mixtures thereof in a combined amount of no greater than 0.1 wt.% based on the aerosolisable formulation. In one aspect the
6 aerosolisable formulation contains glycerol, propylene glycol, 1,3-propane diol and mixtures thereof in a combined amount of no greater than 0.01 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains no glycerol, propylene glycol, 1,3-propane diol and mixtures thereof.
In one aspect the aerosolisable formulation contains glycerol, propylene glycol, and mixtures thereof in a combined amount of no greater than 10 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, and mixtures thereof in a combined amount of no greater than 8 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, and mixtures thereof in a combined amount of no greater than 5 wt.%
based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, and mixtures thereof in a combined amount of no greater than 2 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, and mixtures thereof in a combined amount of no greater than 1 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, and mixtures thereof in a combined amount of no greater than 0.5 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, and mixtures thereof in a combined amount of no greater than 0.2 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, and mixtures thereof in a combined amount of no greater than 0.1 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, and mixtures thereof in a combined amount of no greater than 0.01 wt.%
based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains no glycerol, propylene glycol, and mixtures thereof.
In one aspect the aerosolisable formulation contains glycerol in an amount of no greater than 10 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol in an amount of no greater than 8 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol in an amount of no greater than 5 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol in an amount of no greater than 2 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol in an amount of no greater than 1 wt.% based on the aerosolisable formulation.
In one aspect the aerosolisable formulation contains glycerol in an amount of no greater than 0.5 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation
In one aspect the aerosolisable formulation contains glycerol, propylene glycol, and mixtures thereof in a combined amount of no greater than 10 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, and mixtures thereof in a combined amount of no greater than 8 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, and mixtures thereof in a combined amount of no greater than 5 wt.%
based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, and mixtures thereof in a combined amount of no greater than 2 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, and mixtures thereof in a combined amount of no greater than 1 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, and mixtures thereof in a combined amount of no greater than 0.5 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, and mixtures thereof in a combined amount of no greater than 0.2 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, and mixtures thereof in a combined amount of no greater than 0.1 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, and mixtures thereof in a combined amount of no greater than 0.01 wt.%
based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains no glycerol, propylene glycol, and mixtures thereof.
In one aspect the aerosolisable formulation contains glycerol in an amount of no greater than 10 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol in an amount of no greater than 8 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol in an amount of no greater than 5 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol in an amount of no greater than 2 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol in an amount of no greater than 1 wt.% based on the aerosolisable formulation.
In one aspect the aerosolisable formulation contains glycerol in an amount of no greater than 0.5 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation
7 contains glycerol in an amount of no greater than 0.2 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol in an amount of no greater than 0.1 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol in an amount of no greater than 0.01 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains no glycerol.
In one aspect the aerosolisable formulation contains propylene glycol in an amount of no greater than 10 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains propylene glycol in an amount of no greater than 8 wt.%
based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains propylene glycol in an amount of no greater than 5 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains propylene glycol in an amount of no greater than 2 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains propylene glycol in an amount of no greater than 1 wt.%
based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains propylene glycol in an amount of no greater than 0.5 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains propylene glycol in an amount of no greater than 0.2 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains propylene glycol in an amount of no greater than 0.1 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains propylene glycol in an amount of no greater than 0.01 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains no propylene glycol.
Nicotine The formulation comprises nicotine in protonated form. The formulation may comprise nicotine in unprotonated form. In one aspect the formulation comprises nicotine in unprotonated form and nicotine in monoprotonated form. In one aspect the formulation comprises nicotine in unprotonated form and nicotine in diprotonated form. In one aspect the formulation comprises nicotine in unprotonated form, nicotine in monoprotonated form and nicotine in diprotonated form.
The one or more acids protonate at least 5% of the nicotine. In one aspect, at least 10 wt%
of the nicotine present in the formulation is in protonated form. In one aspect, at least 15 wt% of the nicotine present in the formulation is in protonated form. In one aspect, at least
In one aspect the aerosolisable formulation contains propylene glycol in an amount of no greater than 10 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains propylene glycol in an amount of no greater than 8 wt.%
based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains propylene glycol in an amount of no greater than 5 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains propylene glycol in an amount of no greater than 2 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains propylene glycol in an amount of no greater than 1 wt.%
based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains propylene glycol in an amount of no greater than 0.5 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains propylene glycol in an amount of no greater than 0.2 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains propylene glycol in an amount of no greater than 0.1 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains propylene glycol in an amount of no greater than 0.01 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains no propylene glycol.
Nicotine The formulation comprises nicotine in protonated form. The formulation may comprise nicotine in unprotonated form. In one aspect the formulation comprises nicotine in unprotonated form and nicotine in monoprotonated form. In one aspect the formulation comprises nicotine in unprotonated form and nicotine in diprotonated form. In one aspect the formulation comprises nicotine in unprotonated form, nicotine in monoprotonated form and nicotine in diprotonated form.
The one or more acids protonate at least 5% of the nicotine. In one aspect, at least 10 wt%
of the nicotine present in the formulation is in protonated form. In one aspect, at least 15 wt% of the nicotine present in the formulation is in protonated form. In one aspect, at least
8 20 wt% of the nicotine present in the formulation is in protonated form. In one aspect, at least 25 wt% of the nicotine present in the formulation is in protonated form.
In one aspect, at least 30 wt% of the nicotine present in the formulation is in protonated form. In one aspect, at least 35 wt% of the nicotine present in the formulation is in protonated form. In one aspect, at least 40 wt% of the nicotine present in the formulation is in protonated form.
In one aspect, at least 45 wt% of the nicotine present in the formulation is in protonated form. In one aspect at least 50wt% of the nicotine present in the formulation is in protonated form. In one aspect at least 55wt% of the nicotine present in the formulation is in protonated form. In one aspect at least 60wt% of the nicotine present in the formulation is in protonated form. In one aspect at least 65wt% of the nicotine present in the formulation is in protonated form. In one aspect at least 70wt% of the nicotine present in the formulation is in protonated form. In one aspect at least 75wt% of the nicotine present in the formulation is in protonated form. In one aspect at least 80wt% of the nicotine present in the formulation is in protonated form. In one aspect at least 85wt% of the nicotine present in the formulation is in protonated form. In one aspect at least 90wt% of the nicotine present in the formulation is in protonated form. In one aspect at least 95wt% of the nicotine present in the formulation is in protonated form. In one aspect at least 99wt% of the nicotine present in the formulation is in protonated form. In one aspect at least 99.9wt% of the nicotine present in the formulation is in protonated form.
In one aspect from 5 to 95 wt% of the nicotine present in the formulation is in protonated form. In one aspect from 10 to 95 wt% of the nicotine present in the formulation is in protonated form. In one aspect from 15 to 95 wt% of the nicotine present in the formulation is in protonated form. In one aspect from 20 to 95 wt% of the nicotine present in the formulation is in protonated form. In one aspect from 25 to 95 wt% of the nicotine present in the formulation is in protonated form. In one aspect from 30 to 95 wt% of the nicotine present in the formulation is in protonated form. In one aspect from 35 to 95 wt% of the nicotine present in the formulation is in protonated form. In one aspect from 40 to 95 wt% of the nicotine present in the formulation is in protonated form. In one aspect from 45 to 95 wt% of the nicotine present in the formulation is in protonated form. In one aspect from 50 to 95 wt%
of the nicotine present in the formulation is in protonated form. In one aspect from 55 to 95 wt% of the nicotine present in the formulation is in protonated form. In one aspect from 60 to 95 wt% of the nicotine present in the formulation is in protonated form. In one aspect from 65 to 95 wt% of the nicotine present in the formulation is in protonated form.
In one aspect from 70 to 95 wt% of the nicotine present in the formulation is in protonated form. In one aspect from 75 to 95 wt% of the nicotine present in the formulation is in protonated form. In one aspect from 80 to 95 wt% of the nicotine present in the formulation is in protonated form.
In one aspect, at least 30 wt% of the nicotine present in the formulation is in protonated form. In one aspect, at least 35 wt% of the nicotine present in the formulation is in protonated form. In one aspect, at least 40 wt% of the nicotine present in the formulation is in protonated form.
In one aspect, at least 45 wt% of the nicotine present in the formulation is in protonated form. In one aspect at least 50wt% of the nicotine present in the formulation is in protonated form. In one aspect at least 55wt% of the nicotine present in the formulation is in protonated form. In one aspect at least 60wt% of the nicotine present in the formulation is in protonated form. In one aspect at least 65wt% of the nicotine present in the formulation is in protonated form. In one aspect at least 70wt% of the nicotine present in the formulation is in protonated form. In one aspect at least 75wt% of the nicotine present in the formulation is in protonated form. In one aspect at least 80wt% of the nicotine present in the formulation is in protonated form. In one aspect at least 85wt% of the nicotine present in the formulation is in protonated form. In one aspect at least 90wt% of the nicotine present in the formulation is in protonated form. In one aspect at least 95wt% of the nicotine present in the formulation is in protonated form. In one aspect at least 99wt% of the nicotine present in the formulation is in protonated form. In one aspect at least 99.9wt% of the nicotine present in the formulation is in protonated form.
In one aspect from 5 to 95 wt% of the nicotine present in the formulation is in protonated form. In one aspect from 10 to 95 wt% of the nicotine present in the formulation is in protonated form. In one aspect from 15 to 95 wt% of the nicotine present in the formulation is in protonated form. In one aspect from 20 to 95 wt% of the nicotine present in the formulation is in protonated form. In one aspect from 25 to 95 wt% of the nicotine present in the formulation is in protonated form. In one aspect from 30 to 95 wt% of the nicotine present in the formulation is in protonated form. In one aspect from 35 to 95 wt% of the nicotine present in the formulation is in protonated form. In one aspect from 40 to 95 wt% of the nicotine present in the formulation is in protonated form. In one aspect from 45 to 95 wt% of the nicotine present in the formulation is in protonated form. In one aspect from 50 to 95 wt%
of the nicotine present in the formulation is in protonated form. In one aspect from 55 to 95 wt% of the nicotine present in the formulation is in protonated form. In one aspect from 60 to 95 wt% of the nicotine present in the formulation is in protonated form. In one aspect from 65 to 95 wt% of the nicotine present in the formulation is in protonated form.
In one aspect from 70 to 95 wt% of the nicotine present in the formulation is in protonated form. In one aspect from 75 to 95 wt% of the nicotine present in the formulation is in protonated form. In one aspect from 80 to 95 wt% of the nicotine present in the formulation is in protonated form.
9 In one aspect from 85 to 95 wt% of the nicotine present in the formulation is in protonated form. In one aspect from 90 to 95 wt% of the nicotine present in the formulation is in protonated form.
The relevant amounts of nicotine which are present in the formulation in protonated form are specified herein. These amounts may be readily calculated by one skilled in the art. Nicotine, 3-(1-methylpyrrolidin-2-y1) pyridine, is a diprotic base with pKa of 3.12 for the pyridine ring and 8.02 for the pyrrolidine ring It can exist in pH-dependent protonated (mono- and di-) and non-protonated (free base) forms which have different bioavailability.
H,C1,0 illifrc_Houten The distribution of protonated and non-protonated nicotine will vary at various pH
increments.
r--") H+ 14+ rTh `"1,4 --NH+ r-- = -y NH+
)Lõ
1-1*
The fraction of non-protonated nicotine will be predominant at high pH levels whilst a decrease in the pH will see an increase of the fraction of protonated nicotine (mono- or di-depending on the pH). If the relative fraction of protonated nicotine and the total amount of nicotine in the sample are known, the absolute amount of protonated nicotine can be calculated.
The relative fraction of protonated nicotine in formulation can be calculated by using the Henderson-Hasselbalch equation, which describes the pH as a derivation of the acid dissociation constant equation, and it is extensively employed in chemical and biological systems. Consider the following equilibrium:
B + H > BH+
The Henderson-Hasselbalch equation for this equilibrium is:
[B]
pH yr- pKa 4-[131.1 +1 Where [B] is the amount of non-protonated nicotine (i.e. free base), [BHA] the amount of protonated nicotine (i.e. conjugate acid) and pKa is the reference pKa value for the pyrrolidine ring nitrogen of nicotine (pKa=8.02). The relative fraction of protonated nicotine can be derived from the alpha value of the non-protonated nicotine calculated from the Henderson-Hasselbalch equation as:
[B]
[RH -F1 Voprotonated nicotine ¨ 100 tf [B] *100}
EBB
Determination of pKa values of nicotine formulations was carried out using the basic approach described in "Spectroscopic investigations into the acid¨base properties of nicotine at different temperatures", Peter M. Clayton, Carl A. Vas, Tam T. T. Bui, Alex F. Drake and Kevin McAdam, .Anal. Methods, 2013,5, 81-88.
The one or more acids provide a formulation having a pH of from 4 to 6. In one aspect the one or more acids provide a formulation having a pH of from 4.5 to 6. In one aspect the one or more acids provide a formulation having a pH of from 4 to 5.5. In one aspect the one or more acids provide a formulation having a pH of from 4.5 to 5.5. In one aspect the one or more acids provide a formulation having a pH of from 4.5 to 5. In one aspect the one or more acids provide a formulation having a pH of from 5 to 6. In one aspect the one or more acids provide a formulation having a pH of from 5 to 5.5. In one aspect the one or more acids provide a formulation having a pH of from 5.5 to 6.
Nicotine formulations may be provided having desirable properties of flavour, impact, irritation, smoothness and/or nicotine reward for the user. In one aspect nicotine is present in an amount of no greater than 6 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.01 to 6 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.02 to 6 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.05 to 6 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.08 to 6 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.01 to 5 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.02 to 5 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.05 to 5 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.08 to 5 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of no greater than 4 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.01 to 4 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.02 to 4 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.05 to 4 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.08 to 4 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of no greater than 3 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.01 to 3 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.02 to 3 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.05 to 3 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.08 to 3 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of no greater than 2 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.01 to 2 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.02 to 2 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.05 to 2 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.08 to 2 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of no greater than 1 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.01 to 1 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.02 to 1 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.05 to 1 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.08 to 1 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.1 to 1 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of no greater than 0.5 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.01 to 0.5 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.02 to 0.5 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.05 to 0.5 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.08 to 0.5 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of no greater than 0.2 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.01 to 0.2 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.02 to 0.2 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.05 to 0.2 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.08 to 0.2 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of no greater than 0.1 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.01 to 0.1 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.02 to 0.1 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.05 to 0.1 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.08 to 0.1 wt% based on the total weight of the aerosolisable formulation.
Acid As discussed herein the aerosolisable formulation contains an acid which is at least partially .. water soluble. By the term "at least partially water soluble" it is meant the acid has a solubility in water of at least 2g/L at 20 C. In one aspect the acid has a solubility in water of at least 5g/L at 20 C. In one aspect the acid has a solubility in water of at least 10g/L at 20 C. In one aspect the acid has a solubility in water of at least 20g/L at 20 C. In one aspect the acid has a solubility in water of at least 50g/L at 20 C. In one aspect the acid has a solubility in water of at least 100g/L at 20 C. In one aspect the acid has a solubility in water of at least 200g/L at 20 C. In one aspect the acid has a solubility in water of at least 300g/L
at 20 C. In one aspect the acid has a solubility in water of at least 400g/L
at 20 C. In one aspect the acid has a solubility in water of at least 500g/L at 20 C. In one aspect the acid has a solubility in water of at least 600g/L at 20 C. In one aspect the acid has a solubility in water of at least 700g/L at 20 C. In one aspect the acid has a solubility in water of at least 800g/L at 20 C. In one aspect the acid has a solubility in water of at least 900g/L at 20 C.
In one aspect the acid has a solubility in water of at least 1000g/L at 20 C.
In one aspect the acid has a solubility in water of at least 1100g/L at 20 C.
The acid may be any suitable acid provided of course the acid at least 5 wt%
of the nicotine present in the formulation is in protonated form; and wherein the formulation has a pH of from 4 to 6.
In one aspect the acid is an organic acid. In one aspect the acid is a carboxylic acid. In one aspect the acid is an organic carboxylic acid. In one aspect the acid has a bitter or sour taste. In one aspect the acid has a bitter taste. In one aspect the acid has a sour taste.
In one aspect the acid is selected from the group consisting of citric acid, maleic acid, malic acid, lactic acid, levulinic acid, benzoic acid, sorbic acid, acetic acid and mixtures thereof. In one aspect the acid is selected from the group consisting of citric acid, maleic acid, lactic acid, levulinic acid, benzoic acid, and mixtures thereof. In one aspect the acid is selected from the group consisting of citric acid, benzoic acid, sorbic acid, acetic acid and mixtures thereof. In one aspect the acid is selected from the group consisting of benzoic acid, sorbic acid, acetic acid and mixtures thereof. In one aspect the acid is at least sorbic acid. In one aspect the acid consists of sorbic acid. In one aspect the acid is at least acetic acid. In one aspect the acid consists of acetic acid. In one aspect the acid is at least benzoic acid. In one aspect the acid consists of benzoic acid. In one aspect the acid is at least citric acid. In one aspect the acid consists of citric acid.
In one aspect the acid is selected from acids having a pka of from 2 to 5. In one aspect the acid is a weak acid. In one aspect the acid is a weak organic acid.
The molar ratio of acid to nicotine may be selected as desired. In one aspect the molar ratio of acid to nicotine is from 5:1 to 1:5. In one aspect the molar ratio of acid to nicotine is from 4:1 to 1:4. In one aspect the molar ratio of acid to nicotine is from 3:1 to 1:3. In one aspect the molar ratio of acid to nicotine is from 2:1 to 1:2. In one aspect the molar ratio of acid to nicotine is from 1.5:1 to 1:1.5. In one aspect the molar ratio of acid to nicotine is from 1.2:1 to 1:1.2. In one aspect the molar ratio of acid to nicotine is from 5:1 to 1:1.
In one aspect the molar ratio of acid to nicotine is from 4:1 to 1:1. In one aspect the molar ratio of acid to nicotine is from 3:1 to 1:1. In one aspect the molar ratio of acid to nicotine is from 2:1 to 1:1.
In one aspect the molar ratio of acid to nicotine is from 1.5:1 to 1:1. In one aspect the molar ratio of acid to nicotine is from 1.2:1 to 1:1.
In one aspect the total content of acid present in the formulation is no greater than 5 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no greater than 4 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no greater than 3 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no greater than 2 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no greater than 1 mole equivalents based on the nicotine.
In one aspect the total content of acid present in the formulation is no less than 0.01 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no less than 0.05 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no less than 0.1 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no less than 0.2 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no less than 0.3 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no less than 0.4 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no less than 0.5 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no less than 0.7 mole equivalents based on the nicotine.
The acid may be present in any suitable amount. In one aspect the acid is present in an amount of no greater than 6 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.01 to 6 wt% based on the aerosolisable formulation.
In one aspect the acid is present in an amount of from 0.02 to 6 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.05 to 6 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.08 to 6 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.01 to 5 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.02 to 5 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.05 to 5 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.08 to 5 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of no greater than 4 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.01 to 4 wt% based on the aerosolisable formulation.
In one aspect the acid is present in an amount of from 0.02 to 4 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.05 to 4 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.08 to 4 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of no greater than 3 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.01 to 3 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.02 to 3 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.05 to 3 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.08 to 3 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of no greater than 2 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.01 to 2 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.02 to 2 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.05 to 2 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.08 to 2 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of no greater than 1 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.01 to 1 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.02 to 1 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.05 to 1 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.08 to 1 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.1 to 1 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of no greater than 0.6 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.01 to 0.6 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.02 to 0.6 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.05 to 0.6 wt% based on the aerosolisable formulation.
In one aspect the acid is present in an amount of from 0.08 to 0.6 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.1 to 0.6 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of no greater than 0.5 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.01 to 0.5 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.02 to 0.5 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.05 to 0.5 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.08 to 0.5 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of no greater than 0.2 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.01 to 0.2 wt% based on the aerosolisable formulation.
In one aspect the acid is present in an amount of from 0.02 to 0.2 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.05 to 0.2 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.08 to 0.2 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of no greater than 0.1 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.01 to 0.1 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.02 to 0.1 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.05 to 0.1 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.08 to 0.1 wt% based on the aerosolisable formulation.
The amount of acid and the solubility of the acid may be selected such that a given amount of the acid will dissolve in the water. In one aspect at 20 C at least 20% of the acid dissolves in the water. In one aspect at 25 C at least 20% of the acid dissolves in the water.
In one aspect at 30 C at least 20% of the acid dissolves in the water. In one aspect at 20 C
at least 35% of the acid dissolves in the water. In one aspect at 20 C at least 40% of the acid dissolves in the water. In one aspect at 20 C at least 45% of the acid dissolves in the water. In one aspect at 20 C at least 50% of the acid dissolves in the water.
In one aspect at 20 C at least 55% of the acid dissolves in the water. In one aspect at 20 C at least 60%
of the acid dissolves in the water. In one aspect at 20 C at least 65% of the acid dissolves in the water. In one aspect at 20 C at least 70% of the acid dissolves in the water. In one aspect at 20 C at least 75% of the acid dissolves in the water. In one aspect at 20 C at least 80% of the acid dissolves in the water.
Formulation In one aspect the aerosolisable formulation further comprises one or more flavours or flavouring components. As used herein, the terms "flavour" and "flavourant"
refer to materials which, where local regulations permit, may be used to create a desired taste or aroma in a product for adult consumers. They may include extracts (e.g.
liquorice, hydrangea, Japanese white bark magnolia leaf, chamomile, fenugreek, clove, menthol, Japanese mint, aniseed, cinnamon, herb, wintergreen, cherry, berry, peach, apple, Drambuie, bourbon, scotch, whiskey, spearmint, peppermint, lavender, cardamom, celery, cascarilla, nutmeg, sandalwood, bergamot, geranium, honey essence, rose oil, vanilla, lemon oil, orange oil, cassia, caraway, cognac, jasmine, ylang-ylang, sage, fennel, piment, ginger, anise, coriander, coffee, or a mint oil from any species of the genus Mentha), flavour enhancers, bitterness receptor site blockers, sensorial receptor site activators or stimulators, sugars and/or sugar substitutes (e.g., sucralose, acesulfame potassium, aspartame, saccharine, cyclamates, lactose, sucrose, glucose, fructose, sorbitol, or mannitol), and other additives such as charcoal, chlorophyll, minerals, botanicals, or breath freshening agents.
They may be imitation, synthetic or natural ingredients or blends thereof.
They may be in any suitable form, for example, oil, liquid, or powder. The one or more flavours may be selected from the group consisting of (4-(para-)methoxypheny1)-2-butanone, vanillin, y-undecalactone, menthone, 5-propenyl guaethol, menthol, para-mentha-8-thioI-3-one and mixtures thereof. In one aspect the flavour is at least menthol.
If present, the one or more flavours may be present in any suitable amount. In one aspect the one or more flavours are present in a total amount of no greater than 10 wt.% based on the aerosolisable formulation. In one aspect the one or more flavours are present in a total amount of no greater than 7 wt.% based on the aerosolisable formulation. In one aspect the one or more flavours are present in a total amount of no greater than 5 wt.%
based on the aerosolisable formulation. In one aspect the one or more flavours are present in a total amount of no greater than 4 wt.% based on the aerosolisable formulation. In one aspect the one or more flavours are present in a total amount of no greater than 3 wt.%
based on the aerosolisable formulation. In one aspect the one or more flavours are present in a total amount of no greater than 2wt.% based on the aerosolisable formulation. In one aspect the one or more flavours are present in a total amount of no greater than 1wt. /0 based on the aerosolisable formulation.
In one aspect the one or more flavours are present in a total amount of from 0.01 to 5wt. /0 based on the aerosolisable formulation. In one aspect the one or more flavours are present in a total amount of from 0.01 to 4wt.% based on the aerosolisable formulation. In one aspect the one or more flavours are present in a total amount of from 0.01 to 3wt. /0 based on the aerosolisable formulation. In one aspect the one or more flavours are present in a total amount of from 0.01 to 2wt.% based on the aerosolisable formulation. In one aspect the one or more flavours are present in a total amount of from 0.01 to 1wt.% based on the aerosolisable formulation. In one aspect the one or more flavours are present in a total amount of from 0.01 to 0.5wt.% based on the aerosolisable formulation.
As discussed above, in the present system the number of components present may be reduced leading to less chance of forming breakdown products/toxicants. Thus in one aspect there is provided an aerosolisable formulation as described herein consisting of (i) water; (ii) nicotine; (iii) the acid; and (iv) optionally one or more flavours. In one aspect there is provided an aerosolisable formulation as described herein consisting of (i) water; (ii) nicotine;
(iii) the acid; and (iv) one or more flavours. In one aspect there is provided an aerosolisable formulation as described herein consisting of (i) water; (ii) nicotine; and (iii) the acid.
One or more cyclodextrins may or may not be present in any suitable amount in the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 12 wt.% based on the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 10 wt.% based on the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 9 wt.% based on the aerosolisable formulation.
In one aspect the one or more cyclodextrins are present in a total amount of no greater than 8 wt.% based on the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 7 wt.% based on the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 6 wt.%
based on the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 5 wt.% based on the aerosolisable formulation.
In one aspect the one or more cyclodextrins are present in a total amount of no greater than 4 wt.% based on the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 3 wt.% based on the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 2 wt.% based on the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 1 wt.% based on the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 0.1 wt.% based on the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 0.01 wt.%
based on the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 0.001 wt.% based on the aerosolisable formulation.
The one or more cyclodextrins may be selected from the group consisting of unsubstituted cyclodextrins, substituted cyclodextrins and mixtures thereof. In one aspect at least one cyclodextrin is an unsubstituted cyclodextrin. In one aspect the one or more cyclodextrins are selected from the group consisting of unsubstituted cyclodextrins. In one aspect at least one cyclodextrin is a substituted cyclodextrin. In one aspect the one or more cyclodextrins are selected from the group consisting of substituted cyclodextrins.
In one aspect the one or more cyclodextrins are selected from the group consisting of unsubstituted (a)-cyclodextrin, substituted (a)-cyclodextrin, unsubstituted (f3)-cyclodextrin, substituted (13)-cyclodextrin, unsubstituted (y)-cyclodextrin, substituted (y)-cyclodextrin, and mixtures thereof. In one aspect the one or more cyclodextrins are selected from the group consisting of unsubstituted (3)-cyclodextrin, substituted (13)-cyclodextrin, and mixtures thereof.
In one aspect the one or more cyclodextrins are selected from the group consisting of unsubstituted (a)-cyclodextrin, unsubstituted (3)-cyclodextrin, unsubstituted (y)-cyclodextrin, and mixtures thereof. In one aspect the one or more cyclodextrins is selected from unsubstituted (3)-cyclodextrin.
In one aspect the one or more cyclodextrins are selected from the group consisting of substituted (a)-cyclodextrin, substituted (3)-cyclodextrin, substituted (y)-cyclodextrin, and mixtures thereof. In one aspect the one or more cyclodextrins is selected from substituted (3)-cyclodextrins. Chemical substitutions at the 2-, 3-, and 6-hydroxyl sites are envisaged, and in particular substitution at the 2-position.
In one aspect the one or more cyclodextrins are selected from the group consisting of 2-hydroxy- propyl-a-cyclodextrin, 2- hydroxy- propy1-3-cyclodextrin, 2-hydroxy-propyl-y-cyclodextrin and mixtures thereof. In one aspect the one or more cyclodextrins is at least 2-hydroxy-propyl-a-cyclodextrin. In one aspect the one or more cyclodextrins is at least 2-hydroxy-propy1-3-cyclodextrin. In one aspect the one or more cyclodextrins is at least 2-hydroxy-propyl-y-cyclodextrin.
2-hydroxy-propyl derivatives of cyclodextrins, such as 2-hydroxy-propyl-p-cyclodextrin have increased solubility in water when compared to base cyclodextrins such as f3-cyclodextrin.
In one aspect the aerosolisable formulation is in liquid form. In one aspect the aerosolisable formulation is not in liquid form. In one aspect if the aerosolisable formulation is in the form of a gel or paste.
In one aspect if the aerosolisable formulation contains one or more cyclodextrins, then the aerosolisable formulation contains no flavours that can be encapsulated by the one or more cyclodextrins.
Process As discussed herein, in one aspect there is provided a process for forming an aerosol, the process comprising aerosolising an aerosolisable formulation comprising (i) water in an amount of at least 20 wt.% based on the aerosolisable formulation;
(ii) nicotine; and (iii) an acid which is at least partially water soluble;
wherein at least 5 wt% of the nicotine present in the formulation is in protonated form; and wherein the formulation has a pH of from 4 to 6.
In the process the aerosol may be formed by a process performed at a temperature below 60 C.In the process the aerosol may be formed by a process performed at a temperature below 50 C. In the process the aerosol may be formed by a process performed at a temperature below 40 C. In the process the aerosol may be formed by a process performed at a temperature below 30 C. In the process the aerosol may be formed by a process performed at a temperature below 25 C. In the process the aerosol may be formed by a process which does not involve heating.
In the process the aerosol may be formed by applying ultrasonic energy to the aerosolisable formulation.
In one aspect the aerosol of the aerosolised formulation has a D50 of from 2 to 6pm.
References in the present specification to particle size distribution, D50, D10 or D90 refer to values measured in accordance with British and European Pharmacopoeia, 2.9.31 Particle Size Analysis By Laser Light Diffraction (see BRITISH PHARMACOPOEIA
COMMISSION.
(2014), British Pharmacopoeia. London, England: Stationery Office and COUNCIL
OF
EUROPE. (2013). European Pharmacopoeia. Strasbourg, France: Council of Europe). The terms D50, Dv50 and Dx50 are interchangeable. The terms D10, Dv10 and Dx10 are interchangeable. The terms D90, Dv90 and Dx90 are interchangeable.
In one aspect the aerosol has a D50 of from 2.5 to 6pm. In one aspect the aerosol has a D50 of from 3 to 6pm. In one aspect the aerosol has a D50 of from 3.5 to 6pm.
In one aspect the aerosol has a D50 of from 4 to 6pm. In one aspect the aerosol has a D50 of from 4.5 to 6pm. In one aspect the aerosol has a D50 of from 5 to 6pm. In one aspect the aerosol has a D50 of from 2.5 to 5.5pm. In one aspect the aerosol has a D50 of from 3 to 5.5pm. In one aspect the aerosol has a D50 of from 3.5 to 5.5pm. In one aspect the aerosol has a D50 of from 4 to 5.5pm. In one aspect the aerosol has a D50 of from 4.5 to 5.5pm. In one aspect the aerosol has a D50 of from 5 to 5.5pm.
In one aspect the aerosol has a D10 of at least 0.5pm. In one aspect the aerosol has a D10 of at least 1pm. In one aspect the aerosol has a D10 of at least 2pm.
In one aspect the aerosol has a D90 of no greater than 15pm. In one aspect the aerosol has a D90 of no greater than 12pm. In one aspect the aerosol has a D90 of no greater than 10pm.
In one aspect D50 is measured after exclusion of particles having a particle size of less than 1pm. In one aspect D10 is measured after exclusion of particles having a particle size of less than 1pm. In one aspect D90 is measured after exclusion of particles having a particle size of less than 1pm.
We have identified a water-based system which, by careful selection of the particle size distribution of the aerosol, delivers water droplets containing the active agent into desirable areas of the lungs, such as the deep lung. We have identified that in water-based aerosols, the droplets have a tendency to evaporate and decrease in size when inhaled by the user.
Therefore the specific selection of particle size described herein addresses the reduction of size through evaporation and still delivers the active agent into the desired area of the lungs.
These problems and the choice made in the present invention is in contrast to the prior liquids based on glycerol and propylene glycol in which the liquid droplets tend to adhere to moisture within the lungs and thereby increase in size when inhaled.
The formulation may be contained or delivered by any means. In one aspect the present invention provides a contained aerosolisable formulation comprising (a) one or more containers; and (b) an aerosolisable formulation as defined herein. The container may be any suitable container, for example to allow for the storage or delivery of the formulation. In one aspect the container is configured for engagement with an electronic aerosol provision system. The container may be configured to become fluidly in communication with an electronic aerosol provision system so that formulation may be delivered to the electronic aerosol provision system. As described above, the present disclosure relates to container which may be used in an electronic aerosol provision system, such as an e-cigarette.
Throughout the following description the term "e-cigarette" is used; however, this term may be used interchangeably with electronic aerosol provision system.
As discussed herein, the container of the present invention is typically provided for the delivery of aerosolisable formulation to or within an e-cigarette. The aerosolisable formulation may be held within an e-cigarette or may be sold as a separate container for subsequent use with or in an e-cigarette. As understood by one skilled in the art, e-cigarettes may contain a unit known as a detachable cartomiser which typically comprises a reservoir of aerosolisable formulation, and an aerosoliser such as a wick material and a heating element for vaporising the aerosolisable formulation. In some e-cigarettes, the cartomiser is part of a single-piece device and is not detachable. In one aspect the container is a cartomiser or is part of a cartomiser. In one aspect the container is not a cartomiser or part of a cartomiser and is a container, such as a tank, which may be used to deliver nicotine formulation to or within an e-cigarette.
In one aspect the container is part of an e-cigarette. Therefore in a further aspect the present invention provides an electronic aerosol provision system comprising: an aerosolisable formulation as defined herein; an aerosoliser for aerosolising formulation for inhalation by a user of the electronic aerosol provision system; and a power supply comprising a cell or battery for supplying power to the aerosoliser.
In addition to the aerosolisable formulation of the present invention and to systems such as containers and electronic aerosol provision systems containing the same, the present invention provides a process for improving the sensory properties of an aerosolised nicotine.
In a further aspect the present invention provides a process for improving the storage stability of an aerosolised nicotine formulation.
Reference to an improvement in the sensory properties of a vaporised nicotine solution refer may include an improvement in the smoothness of the vaporised nicotine solution as perceived by a user.
The process of the present invention may comprises additional steps either before the steps listed, after the steps listed or between one or more of the steps listed.
BRIEF DESCRIPTION OF THE DRAWINGS
The present invention will now be described in further detail by way of example only with reference to the accompanying figure in which:-Figure 1 shows a graph illustrating variation of p5K32 with nicotine concentration The invention will now be described with reference to the following non-limiting examples.
Examples Example 1 A series of tests were conducted using a formulation containing 90.0% (w/w) water, 9.0% 2-hydroxy-propyl-p-cyclodextrin, 0.9% I-menthol, and 0.1% nicotine. With no additional components, the pH of this formulation is approximately 8. With pH treatment using certain acids, preservative effects will be observed in the pH range of 4 ¨ 6.
In this example, the viable micro-organisms are fungal: Pseudomonas aeruginosa, Staphylococcus aureus, Aspergillus brasiliensis, Candida albicans and Escherichia coli, .. The Council of Europe (2011) (European Pharmacopoeia. Strasbourg, France:
Council of Europe) has published standards relating to the efficacy of antimicrobial preservation as a relevant test methodology for oral preparations. Acceptance criteria for Fungi is expressed as a log reduction in the number of viable-micro-organisms after 14 days against the value obtained for the inoculum (control sample ¨ e.g. <0 days).
Acceptance criteria for the efficacy of antimicrobial preservation may be based on those published in the literature for similar aerosol products (European Pharmacopoeia 2011).
Suitable statistical models are also recommended but not mandatory to contextualise any resulting data. An example includes Analysis of Variance (ANOVA) and at a suitable confidence interval ¨ e.g. 95%.
Example 2 Formulations with different acids at a range of pHs (4 to 6) were tested for 14 and 28 days at 20 C for microbial growth. The acids tested were benzoic acid, sorbic acid and acetic acid.
The following tests were carried out Sample preparation A 1 in 10 dilution was prepared using Neutraliser as a diluent. Further dilutions were performed to create 1/100 and 1/1000 dilutions.
Determining the initial bioburden of the test product A 1/10, 1/100 & 1/1000 dilution of the test sample in Neutraliser was prepared. The sample was pour plated and incubated. For the product, the initial bioburden was determined.
Method Suitability Testing for Total Aerobic Microbial Count (TAMC) and Total Yeasts and Mould Count (TYMC) 1% Nicotine Solution in de-ionised water Each dilution of test product in diluent (Neutraliser), the test product and a positive control (diluent without product) were inoculated with test microorganisms. The test microorganisms were Aspergifius brasiliensis, Candida albicans, Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
The method tested duplicate plates of test product and positive controls (diluent without product) inoculated with test organisms. Duplicate plates of test product in diluent (Neutraliser) were also included. All samples were incubated.
The following samples were tested Sample Flavour, Water, Nicotine, 2-hydroxy-propyl- Acid Acid, pH
w/w % w/w % w/w % ii-cyclodextrin, w/w %
w/w /0 2.1 0.9 89.9 0.1 9 benzoic 0.1 6 L-menthol 2.2 0.9 89.5 0.1 9 sorbic 0.5 L-menthol 2.3 7 87.8 1 3 acetic 1.2 Apple BAT: P10018254; 81883115- DYC: P115645PCT
ci ID
FIP
.4 X TIVffil,CrOPTUMOrncou fere aS f0.09W5 (D
Z.:
K) C
:g O :=, a, Er Sample 2.1 I.-menthol =
=ISr.
x aN
o 'cak 0 Organism Control 14 days 28 days Pass/Fail 4*, CD
R* Control Count Test Count % Increase/ Test Count % Increase/
0_ (cfu/mL) , decrease in cfu , (cfu/mL) decrease in cfu N) .
ry Pseudomonas 1.2*.108 9.5 x 102 99.9% decrease 5.2 x 102 99.9% decrease Pass f? aeru inosa Staphylococcus 1.4 x 106 0 100% decrease 0 100% decrease Pass Fo' aureus Escherichia coli 7.1 x 105 0 100% decrease 0 100% decrease Pass Candida albicans 2.1 x 105 0 100% decrease 0 100% decrease Pass Aspergillus 3.2 x 105 9.1 x 10 71.5% decrease 7.2 x 104 78% decrease Pass _ brasiliensis , Sample 2,2 L-menthol Organism Control 14 days 28 days Pass/Fail Control Count Test Count % Increase/ Test Count % Increase/
(cfu/mL) decrease in cfu (cfu/mL) decrease in cfu Pseudomonas 12 i0 0 100% decrease 0 100% decrease Pass aeru inosa Staphylococcus 1.4 x 106 0 100% decrease 0 100% decrease Pass aureus Escherichia coli 7.1 x 105 0 100% decrease 0 100% decrease Pass a Candida albicans 2.1 x 106 0 100% decrease 0 100% decrease Pass =:
Aspergillus 3_2 x 10 0 100% decrease 0 100% decrease Pass :#
brasiliensis #
'I
õet BAT: P10018254; 81883115- DYC: P115645PCT
ci 0, Sarni;le 2.3 ti*
ar ...4 X
CD
.0 :gc 0 Organism Control 14 days 28 days Pass/Fail E4-==i, ID Control Count Test Count % Increase/ Test Count % Increase/ =
iir ISr.
x cfuimL decrease in cfu cfu/mL
decrease in cfu aN
'cak 0 Pseudomonas 1.4 x10 0 100% decrease 0 100% decrease Pass 4*, CD
R* aeru inosa 0_ N) Staphylococcus 2.0 x 106 0 100% decrease 0 100% decrease Pass ry aureus f?
Escherichia coil 2.0 x 106 0 100% decrease 0 100% decrease Pass '8 Candida albicans 1.7 x 106 0 100% decrease 0 100% decrease Pass Aspergillus 4.9 x 105 0 100% decrease 0 100% decrease Pass brasiliensis Each of samples 2:1*2 2 and2Zwere found to significantly inhibit microbial growth. In respect of the majority of samples tested a 100%
INI 5 decrease in was observed.
a #
.8:
..,,,, Various modifications and variations of the present invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention.
Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in chemistry or related fields are intended to be within the scope of the following claims.
The relevant amounts of nicotine which are present in the formulation in protonated form are specified herein. These amounts may be readily calculated by one skilled in the art. Nicotine, 3-(1-methylpyrrolidin-2-y1) pyridine, is a diprotic base with pKa of 3.12 for the pyridine ring and 8.02 for the pyrrolidine ring It can exist in pH-dependent protonated (mono- and di-) and non-protonated (free base) forms which have different bioavailability.
H,C1,0 illifrc_Houten The distribution of protonated and non-protonated nicotine will vary at various pH
increments.
r--") H+ 14+ rTh `"1,4 --NH+ r-- = -y NH+
)Lõ
1-1*
The fraction of non-protonated nicotine will be predominant at high pH levels whilst a decrease in the pH will see an increase of the fraction of protonated nicotine (mono- or di-depending on the pH). If the relative fraction of protonated nicotine and the total amount of nicotine in the sample are known, the absolute amount of protonated nicotine can be calculated.
The relative fraction of protonated nicotine in formulation can be calculated by using the Henderson-Hasselbalch equation, which describes the pH as a derivation of the acid dissociation constant equation, and it is extensively employed in chemical and biological systems. Consider the following equilibrium:
B + H > BH+
The Henderson-Hasselbalch equation for this equilibrium is:
[B]
pH yr- pKa 4-[131.1 +1 Where [B] is the amount of non-protonated nicotine (i.e. free base), [BHA] the amount of protonated nicotine (i.e. conjugate acid) and pKa is the reference pKa value for the pyrrolidine ring nitrogen of nicotine (pKa=8.02). The relative fraction of protonated nicotine can be derived from the alpha value of the non-protonated nicotine calculated from the Henderson-Hasselbalch equation as:
[B]
[RH -F1 Voprotonated nicotine ¨ 100 tf [B] *100}
EBB
Determination of pKa values of nicotine formulations was carried out using the basic approach described in "Spectroscopic investigations into the acid¨base properties of nicotine at different temperatures", Peter M. Clayton, Carl A. Vas, Tam T. T. Bui, Alex F. Drake and Kevin McAdam, .Anal. Methods, 2013,5, 81-88.
The one or more acids provide a formulation having a pH of from 4 to 6. In one aspect the one or more acids provide a formulation having a pH of from 4.5 to 6. In one aspect the one or more acids provide a formulation having a pH of from 4 to 5.5. In one aspect the one or more acids provide a formulation having a pH of from 4.5 to 5.5. In one aspect the one or more acids provide a formulation having a pH of from 4.5 to 5. In one aspect the one or more acids provide a formulation having a pH of from 5 to 6. In one aspect the one or more acids provide a formulation having a pH of from 5 to 5.5. In one aspect the one or more acids provide a formulation having a pH of from 5.5 to 6.
Nicotine formulations may be provided having desirable properties of flavour, impact, irritation, smoothness and/or nicotine reward for the user. In one aspect nicotine is present in an amount of no greater than 6 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.01 to 6 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.02 to 6 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.05 to 6 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.08 to 6 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.01 to 5 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.02 to 5 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.05 to 5 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.08 to 5 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of no greater than 4 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.01 to 4 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.02 to 4 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.05 to 4 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.08 to 4 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of no greater than 3 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.01 to 3 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.02 to 3 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.05 to 3 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.08 to 3 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of no greater than 2 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.01 to 2 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.02 to 2 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.05 to 2 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.08 to 2 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of no greater than 1 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.01 to 1 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.02 to 1 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.05 to 1 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.08 to 1 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.1 to 1 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of no greater than 0.5 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.01 to 0.5 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.02 to 0.5 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.05 to 0.5 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.08 to 0.5 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of no greater than 0.2 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.01 to 0.2 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.02 to 0.2 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.05 to 0.2 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.08 to 0.2 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of no greater than 0.1 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.01 to 0.1 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.02 to 0.1 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.05 to 0.1 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.08 to 0.1 wt% based on the total weight of the aerosolisable formulation.
Acid As discussed herein the aerosolisable formulation contains an acid which is at least partially .. water soluble. By the term "at least partially water soluble" it is meant the acid has a solubility in water of at least 2g/L at 20 C. In one aspect the acid has a solubility in water of at least 5g/L at 20 C. In one aspect the acid has a solubility in water of at least 10g/L at 20 C. In one aspect the acid has a solubility in water of at least 20g/L at 20 C. In one aspect the acid has a solubility in water of at least 50g/L at 20 C. In one aspect the acid has a solubility in water of at least 100g/L at 20 C. In one aspect the acid has a solubility in water of at least 200g/L at 20 C. In one aspect the acid has a solubility in water of at least 300g/L
at 20 C. In one aspect the acid has a solubility in water of at least 400g/L
at 20 C. In one aspect the acid has a solubility in water of at least 500g/L at 20 C. In one aspect the acid has a solubility in water of at least 600g/L at 20 C. In one aspect the acid has a solubility in water of at least 700g/L at 20 C. In one aspect the acid has a solubility in water of at least 800g/L at 20 C. In one aspect the acid has a solubility in water of at least 900g/L at 20 C.
In one aspect the acid has a solubility in water of at least 1000g/L at 20 C.
In one aspect the acid has a solubility in water of at least 1100g/L at 20 C.
The acid may be any suitable acid provided of course the acid at least 5 wt%
of the nicotine present in the formulation is in protonated form; and wherein the formulation has a pH of from 4 to 6.
In one aspect the acid is an organic acid. In one aspect the acid is a carboxylic acid. In one aspect the acid is an organic carboxylic acid. In one aspect the acid has a bitter or sour taste. In one aspect the acid has a bitter taste. In one aspect the acid has a sour taste.
In one aspect the acid is selected from the group consisting of citric acid, maleic acid, malic acid, lactic acid, levulinic acid, benzoic acid, sorbic acid, acetic acid and mixtures thereof. In one aspect the acid is selected from the group consisting of citric acid, maleic acid, lactic acid, levulinic acid, benzoic acid, and mixtures thereof. In one aspect the acid is selected from the group consisting of citric acid, benzoic acid, sorbic acid, acetic acid and mixtures thereof. In one aspect the acid is selected from the group consisting of benzoic acid, sorbic acid, acetic acid and mixtures thereof. In one aspect the acid is at least sorbic acid. In one aspect the acid consists of sorbic acid. In one aspect the acid is at least acetic acid. In one aspect the acid consists of acetic acid. In one aspect the acid is at least benzoic acid. In one aspect the acid consists of benzoic acid. In one aspect the acid is at least citric acid. In one aspect the acid consists of citric acid.
In one aspect the acid is selected from acids having a pka of from 2 to 5. In one aspect the acid is a weak acid. In one aspect the acid is a weak organic acid.
The molar ratio of acid to nicotine may be selected as desired. In one aspect the molar ratio of acid to nicotine is from 5:1 to 1:5. In one aspect the molar ratio of acid to nicotine is from 4:1 to 1:4. In one aspect the molar ratio of acid to nicotine is from 3:1 to 1:3. In one aspect the molar ratio of acid to nicotine is from 2:1 to 1:2. In one aspect the molar ratio of acid to nicotine is from 1.5:1 to 1:1.5. In one aspect the molar ratio of acid to nicotine is from 1.2:1 to 1:1.2. In one aspect the molar ratio of acid to nicotine is from 5:1 to 1:1.
In one aspect the molar ratio of acid to nicotine is from 4:1 to 1:1. In one aspect the molar ratio of acid to nicotine is from 3:1 to 1:1. In one aspect the molar ratio of acid to nicotine is from 2:1 to 1:1.
In one aspect the molar ratio of acid to nicotine is from 1.5:1 to 1:1. In one aspect the molar ratio of acid to nicotine is from 1.2:1 to 1:1.
In one aspect the total content of acid present in the formulation is no greater than 5 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no greater than 4 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no greater than 3 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no greater than 2 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no greater than 1 mole equivalents based on the nicotine.
In one aspect the total content of acid present in the formulation is no less than 0.01 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no less than 0.05 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no less than 0.1 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no less than 0.2 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no less than 0.3 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no less than 0.4 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no less than 0.5 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no less than 0.7 mole equivalents based on the nicotine.
The acid may be present in any suitable amount. In one aspect the acid is present in an amount of no greater than 6 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.01 to 6 wt% based on the aerosolisable formulation.
In one aspect the acid is present in an amount of from 0.02 to 6 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.05 to 6 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.08 to 6 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.01 to 5 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.02 to 5 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.05 to 5 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.08 to 5 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of no greater than 4 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.01 to 4 wt% based on the aerosolisable formulation.
In one aspect the acid is present in an amount of from 0.02 to 4 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.05 to 4 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.08 to 4 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of no greater than 3 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.01 to 3 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.02 to 3 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.05 to 3 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.08 to 3 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of no greater than 2 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.01 to 2 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.02 to 2 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.05 to 2 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.08 to 2 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of no greater than 1 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.01 to 1 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.02 to 1 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.05 to 1 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.08 to 1 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.1 to 1 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of no greater than 0.6 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.01 to 0.6 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.02 to 0.6 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.05 to 0.6 wt% based on the aerosolisable formulation.
In one aspect the acid is present in an amount of from 0.08 to 0.6 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.1 to 0.6 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of no greater than 0.5 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.01 to 0.5 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.02 to 0.5 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.05 to 0.5 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.08 to 0.5 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of no greater than 0.2 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.01 to 0.2 wt% based on the aerosolisable formulation.
In one aspect the acid is present in an amount of from 0.02 to 0.2 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.05 to 0.2 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.08 to 0.2 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of no greater than 0.1 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.01 to 0.1 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.02 to 0.1 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.05 to 0.1 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.08 to 0.1 wt% based on the aerosolisable formulation.
The amount of acid and the solubility of the acid may be selected such that a given amount of the acid will dissolve in the water. In one aspect at 20 C at least 20% of the acid dissolves in the water. In one aspect at 25 C at least 20% of the acid dissolves in the water.
In one aspect at 30 C at least 20% of the acid dissolves in the water. In one aspect at 20 C
at least 35% of the acid dissolves in the water. In one aspect at 20 C at least 40% of the acid dissolves in the water. In one aspect at 20 C at least 45% of the acid dissolves in the water. In one aspect at 20 C at least 50% of the acid dissolves in the water.
In one aspect at 20 C at least 55% of the acid dissolves in the water. In one aspect at 20 C at least 60%
of the acid dissolves in the water. In one aspect at 20 C at least 65% of the acid dissolves in the water. In one aspect at 20 C at least 70% of the acid dissolves in the water. In one aspect at 20 C at least 75% of the acid dissolves in the water. In one aspect at 20 C at least 80% of the acid dissolves in the water.
Formulation In one aspect the aerosolisable formulation further comprises one or more flavours or flavouring components. As used herein, the terms "flavour" and "flavourant"
refer to materials which, where local regulations permit, may be used to create a desired taste or aroma in a product for adult consumers. They may include extracts (e.g.
liquorice, hydrangea, Japanese white bark magnolia leaf, chamomile, fenugreek, clove, menthol, Japanese mint, aniseed, cinnamon, herb, wintergreen, cherry, berry, peach, apple, Drambuie, bourbon, scotch, whiskey, spearmint, peppermint, lavender, cardamom, celery, cascarilla, nutmeg, sandalwood, bergamot, geranium, honey essence, rose oil, vanilla, lemon oil, orange oil, cassia, caraway, cognac, jasmine, ylang-ylang, sage, fennel, piment, ginger, anise, coriander, coffee, or a mint oil from any species of the genus Mentha), flavour enhancers, bitterness receptor site blockers, sensorial receptor site activators or stimulators, sugars and/or sugar substitutes (e.g., sucralose, acesulfame potassium, aspartame, saccharine, cyclamates, lactose, sucrose, glucose, fructose, sorbitol, or mannitol), and other additives such as charcoal, chlorophyll, minerals, botanicals, or breath freshening agents.
They may be imitation, synthetic or natural ingredients or blends thereof.
They may be in any suitable form, for example, oil, liquid, or powder. The one or more flavours may be selected from the group consisting of (4-(para-)methoxypheny1)-2-butanone, vanillin, y-undecalactone, menthone, 5-propenyl guaethol, menthol, para-mentha-8-thioI-3-one and mixtures thereof. In one aspect the flavour is at least menthol.
If present, the one or more flavours may be present in any suitable amount. In one aspect the one or more flavours are present in a total amount of no greater than 10 wt.% based on the aerosolisable formulation. In one aspect the one or more flavours are present in a total amount of no greater than 7 wt.% based on the aerosolisable formulation. In one aspect the one or more flavours are present in a total amount of no greater than 5 wt.%
based on the aerosolisable formulation. In one aspect the one or more flavours are present in a total amount of no greater than 4 wt.% based on the aerosolisable formulation. In one aspect the one or more flavours are present in a total amount of no greater than 3 wt.%
based on the aerosolisable formulation. In one aspect the one or more flavours are present in a total amount of no greater than 2wt.% based on the aerosolisable formulation. In one aspect the one or more flavours are present in a total amount of no greater than 1wt. /0 based on the aerosolisable formulation.
In one aspect the one or more flavours are present in a total amount of from 0.01 to 5wt. /0 based on the aerosolisable formulation. In one aspect the one or more flavours are present in a total amount of from 0.01 to 4wt.% based on the aerosolisable formulation. In one aspect the one or more flavours are present in a total amount of from 0.01 to 3wt. /0 based on the aerosolisable formulation. In one aspect the one or more flavours are present in a total amount of from 0.01 to 2wt.% based on the aerosolisable formulation. In one aspect the one or more flavours are present in a total amount of from 0.01 to 1wt.% based on the aerosolisable formulation. In one aspect the one or more flavours are present in a total amount of from 0.01 to 0.5wt.% based on the aerosolisable formulation.
As discussed above, in the present system the number of components present may be reduced leading to less chance of forming breakdown products/toxicants. Thus in one aspect there is provided an aerosolisable formulation as described herein consisting of (i) water; (ii) nicotine; (iii) the acid; and (iv) optionally one or more flavours. In one aspect there is provided an aerosolisable formulation as described herein consisting of (i) water; (ii) nicotine;
(iii) the acid; and (iv) one or more flavours. In one aspect there is provided an aerosolisable formulation as described herein consisting of (i) water; (ii) nicotine; and (iii) the acid.
One or more cyclodextrins may or may not be present in any suitable amount in the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 12 wt.% based on the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 10 wt.% based on the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 9 wt.% based on the aerosolisable formulation.
In one aspect the one or more cyclodextrins are present in a total amount of no greater than 8 wt.% based on the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 7 wt.% based on the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 6 wt.%
based on the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 5 wt.% based on the aerosolisable formulation.
In one aspect the one or more cyclodextrins are present in a total amount of no greater than 4 wt.% based on the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 3 wt.% based on the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 2 wt.% based on the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 1 wt.% based on the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 0.1 wt.% based on the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 0.01 wt.%
based on the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 0.001 wt.% based on the aerosolisable formulation.
The one or more cyclodextrins may be selected from the group consisting of unsubstituted cyclodextrins, substituted cyclodextrins and mixtures thereof. In one aspect at least one cyclodextrin is an unsubstituted cyclodextrin. In one aspect the one or more cyclodextrins are selected from the group consisting of unsubstituted cyclodextrins. In one aspect at least one cyclodextrin is a substituted cyclodextrin. In one aspect the one or more cyclodextrins are selected from the group consisting of substituted cyclodextrins.
In one aspect the one or more cyclodextrins are selected from the group consisting of unsubstituted (a)-cyclodextrin, substituted (a)-cyclodextrin, unsubstituted (f3)-cyclodextrin, substituted (13)-cyclodextrin, unsubstituted (y)-cyclodextrin, substituted (y)-cyclodextrin, and mixtures thereof. In one aspect the one or more cyclodextrins are selected from the group consisting of unsubstituted (3)-cyclodextrin, substituted (13)-cyclodextrin, and mixtures thereof.
In one aspect the one or more cyclodextrins are selected from the group consisting of unsubstituted (a)-cyclodextrin, unsubstituted (3)-cyclodextrin, unsubstituted (y)-cyclodextrin, and mixtures thereof. In one aspect the one or more cyclodextrins is selected from unsubstituted (3)-cyclodextrin.
In one aspect the one or more cyclodextrins are selected from the group consisting of substituted (a)-cyclodextrin, substituted (3)-cyclodextrin, substituted (y)-cyclodextrin, and mixtures thereof. In one aspect the one or more cyclodextrins is selected from substituted (3)-cyclodextrins. Chemical substitutions at the 2-, 3-, and 6-hydroxyl sites are envisaged, and in particular substitution at the 2-position.
In one aspect the one or more cyclodextrins are selected from the group consisting of 2-hydroxy- propyl-a-cyclodextrin, 2- hydroxy- propy1-3-cyclodextrin, 2-hydroxy-propyl-y-cyclodextrin and mixtures thereof. In one aspect the one or more cyclodextrins is at least 2-hydroxy-propyl-a-cyclodextrin. In one aspect the one or more cyclodextrins is at least 2-hydroxy-propy1-3-cyclodextrin. In one aspect the one or more cyclodextrins is at least 2-hydroxy-propyl-y-cyclodextrin.
2-hydroxy-propyl derivatives of cyclodextrins, such as 2-hydroxy-propyl-p-cyclodextrin have increased solubility in water when compared to base cyclodextrins such as f3-cyclodextrin.
In one aspect the aerosolisable formulation is in liquid form. In one aspect the aerosolisable formulation is not in liquid form. In one aspect if the aerosolisable formulation is in the form of a gel or paste.
In one aspect if the aerosolisable formulation contains one or more cyclodextrins, then the aerosolisable formulation contains no flavours that can be encapsulated by the one or more cyclodextrins.
Process As discussed herein, in one aspect there is provided a process for forming an aerosol, the process comprising aerosolising an aerosolisable formulation comprising (i) water in an amount of at least 20 wt.% based on the aerosolisable formulation;
(ii) nicotine; and (iii) an acid which is at least partially water soluble;
wherein at least 5 wt% of the nicotine present in the formulation is in protonated form; and wherein the formulation has a pH of from 4 to 6.
In the process the aerosol may be formed by a process performed at a temperature below 60 C.In the process the aerosol may be formed by a process performed at a temperature below 50 C. In the process the aerosol may be formed by a process performed at a temperature below 40 C. In the process the aerosol may be formed by a process performed at a temperature below 30 C. In the process the aerosol may be formed by a process performed at a temperature below 25 C. In the process the aerosol may be formed by a process which does not involve heating.
In the process the aerosol may be formed by applying ultrasonic energy to the aerosolisable formulation.
In one aspect the aerosol of the aerosolised formulation has a D50 of from 2 to 6pm.
References in the present specification to particle size distribution, D50, D10 or D90 refer to values measured in accordance with British and European Pharmacopoeia, 2.9.31 Particle Size Analysis By Laser Light Diffraction (see BRITISH PHARMACOPOEIA
COMMISSION.
(2014), British Pharmacopoeia. London, England: Stationery Office and COUNCIL
OF
EUROPE. (2013). European Pharmacopoeia. Strasbourg, France: Council of Europe). The terms D50, Dv50 and Dx50 are interchangeable. The terms D10, Dv10 and Dx10 are interchangeable. The terms D90, Dv90 and Dx90 are interchangeable.
In one aspect the aerosol has a D50 of from 2.5 to 6pm. In one aspect the aerosol has a D50 of from 3 to 6pm. In one aspect the aerosol has a D50 of from 3.5 to 6pm.
In one aspect the aerosol has a D50 of from 4 to 6pm. In one aspect the aerosol has a D50 of from 4.5 to 6pm. In one aspect the aerosol has a D50 of from 5 to 6pm. In one aspect the aerosol has a D50 of from 2.5 to 5.5pm. In one aspect the aerosol has a D50 of from 3 to 5.5pm. In one aspect the aerosol has a D50 of from 3.5 to 5.5pm. In one aspect the aerosol has a D50 of from 4 to 5.5pm. In one aspect the aerosol has a D50 of from 4.5 to 5.5pm. In one aspect the aerosol has a D50 of from 5 to 5.5pm.
In one aspect the aerosol has a D10 of at least 0.5pm. In one aspect the aerosol has a D10 of at least 1pm. In one aspect the aerosol has a D10 of at least 2pm.
In one aspect the aerosol has a D90 of no greater than 15pm. In one aspect the aerosol has a D90 of no greater than 12pm. In one aspect the aerosol has a D90 of no greater than 10pm.
In one aspect D50 is measured after exclusion of particles having a particle size of less than 1pm. In one aspect D10 is measured after exclusion of particles having a particle size of less than 1pm. In one aspect D90 is measured after exclusion of particles having a particle size of less than 1pm.
We have identified a water-based system which, by careful selection of the particle size distribution of the aerosol, delivers water droplets containing the active agent into desirable areas of the lungs, such as the deep lung. We have identified that in water-based aerosols, the droplets have a tendency to evaporate and decrease in size when inhaled by the user.
Therefore the specific selection of particle size described herein addresses the reduction of size through evaporation and still delivers the active agent into the desired area of the lungs.
These problems and the choice made in the present invention is in contrast to the prior liquids based on glycerol and propylene glycol in which the liquid droplets tend to adhere to moisture within the lungs and thereby increase in size when inhaled.
The formulation may be contained or delivered by any means. In one aspect the present invention provides a contained aerosolisable formulation comprising (a) one or more containers; and (b) an aerosolisable formulation as defined herein. The container may be any suitable container, for example to allow for the storage or delivery of the formulation. In one aspect the container is configured for engagement with an electronic aerosol provision system. The container may be configured to become fluidly in communication with an electronic aerosol provision system so that formulation may be delivered to the electronic aerosol provision system. As described above, the present disclosure relates to container which may be used in an electronic aerosol provision system, such as an e-cigarette.
Throughout the following description the term "e-cigarette" is used; however, this term may be used interchangeably with electronic aerosol provision system.
As discussed herein, the container of the present invention is typically provided for the delivery of aerosolisable formulation to or within an e-cigarette. The aerosolisable formulation may be held within an e-cigarette or may be sold as a separate container for subsequent use with or in an e-cigarette. As understood by one skilled in the art, e-cigarettes may contain a unit known as a detachable cartomiser which typically comprises a reservoir of aerosolisable formulation, and an aerosoliser such as a wick material and a heating element for vaporising the aerosolisable formulation. In some e-cigarettes, the cartomiser is part of a single-piece device and is not detachable. In one aspect the container is a cartomiser or is part of a cartomiser. In one aspect the container is not a cartomiser or part of a cartomiser and is a container, such as a tank, which may be used to deliver nicotine formulation to or within an e-cigarette.
In one aspect the container is part of an e-cigarette. Therefore in a further aspect the present invention provides an electronic aerosol provision system comprising: an aerosolisable formulation as defined herein; an aerosoliser for aerosolising formulation for inhalation by a user of the electronic aerosol provision system; and a power supply comprising a cell or battery for supplying power to the aerosoliser.
In addition to the aerosolisable formulation of the present invention and to systems such as containers and electronic aerosol provision systems containing the same, the present invention provides a process for improving the sensory properties of an aerosolised nicotine.
In a further aspect the present invention provides a process for improving the storage stability of an aerosolised nicotine formulation.
Reference to an improvement in the sensory properties of a vaporised nicotine solution refer may include an improvement in the smoothness of the vaporised nicotine solution as perceived by a user.
The process of the present invention may comprises additional steps either before the steps listed, after the steps listed or between one or more of the steps listed.
BRIEF DESCRIPTION OF THE DRAWINGS
The present invention will now be described in further detail by way of example only with reference to the accompanying figure in which:-Figure 1 shows a graph illustrating variation of p5K32 with nicotine concentration The invention will now be described with reference to the following non-limiting examples.
Examples Example 1 A series of tests were conducted using a formulation containing 90.0% (w/w) water, 9.0% 2-hydroxy-propyl-p-cyclodextrin, 0.9% I-menthol, and 0.1% nicotine. With no additional components, the pH of this formulation is approximately 8. With pH treatment using certain acids, preservative effects will be observed in the pH range of 4 ¨ 6.
In this example, the viable micro-organisms are fungal: Pseudomonas aeruginosa, Staphylococcus aureus, Aspergillus brasiliensis, Candida albicans and Escherichia coli, .. The Council of Europe (2011) (European Pharmacopoeia. Strasbourg, France:
Council of Europe) has published standards relating to the efficacy of antimicrobial preservation as a relevant test methodology for oral preparations. Acceptance criteria for Fungi is expressed as a log reduction in the number of viable-micro-organisms after 14 days against the value obtained for the inoculum (control sample ¨ e.g. <0 days).
Acceptance criteria for the efficacy of antimicrobial preservation may be based on those published in the literature for similar aerosol products (European Pharmacopoeia 2011).
Suitable statistical models are also recommended but not mandatory to contextualise any resulting data. An example includes Analysis of Variance (ANOVA) and at a suitable confidence interval ¨ e.g. 95%.
Example 2 Formulations with different acids at a range of pHs (4 to 6) were tested for 14 and 28 days at 20 C for microbial growth. The acids tested were benzoic acid, sorbic acid and acetic acid.
The following tests were carried out Sample preparation A 1 in 10 dilution was prepared using Neutraliser as a diluent. Further dilutions were performed to create 1/100 and 1/1000 dilutions.
Determining the initial bioburden of the test product A 1/10, 1/100 & 1/1000 dilution of the test sample in Neutraliser was prepared. The sample was pour plated and incubated. For the product, the initial bioburden was determined.
Method Suitability Testing for Total Aerobic Microbial Count (TAMC) and Total Yeasts and Mould Count (TYMC) 1% Nicotine Solution in de-ionised water Each dilution of test product in diluent (Neutraliser), the test product and a positive control (diluent without product) were inoculated with test microorganisms. The test microorganisms were Aspergifius brasiliensis, Candida albicans, Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
The method tested duplicate plates of test product and positive controls (diluent without product) inoculated with test organisms. Duplicate plates of test product in diluent (Neutraliser) were also included. All samples were incubated.
The following samples were tested Sample Flavour, Water, Nicotine, 2-hydroxy-propyl- Acid Acid, pH
w/w % w/w % w/w % ii-cyclodextrin, w/w %
w/w /0 2.1 0.9 89.9 0.1 9 benzoic 0.1 6 L-menthol 2.2 0.9 89.5 0.1 9 sorbic 0.5 L-menthol 2.3 7 87.8 1 3 acetic 1.2 Apple BAT: P10018254; 81883115- DYC: P115645PCT
ci ID
FIP
.4 X TIVffil,CrOPTUMOrncou fere aS f0.09W5 (D
Z.:
K) C
:g O :=, a, Er Sample 2.1 I.-menthol =
=ISr.
x aN
o 'cak 0 Organism Control 14 days 28 days Pass/Fail 4*, CD
R* Control Count Test Count % Increase/ Test Count % Increase/
0_ (cfu/mL) , decrease in cfu , (cfu/mL) decrease in cfu N) .
ry Pseudomonas 1.2*.108 9.5 x 102 99.9% decrease 5.2 x 102 99.9% decrease Pass f? aeru inosa Staphylococcus 1.4 x 106 0 100% decrease 0 100% decrease Pass Fo' aureus Escherichia coli 7.1 x 105 0 100% decrease 0 100% decrease Pass Candida albicans 2.1 x 105 0 100% decrease 0 100% decrease Pass Aspergillus 3.2 x 105 9.1 x 10 71.5% decrease 7.2 x 104 78% decrease Pass _ brasiliensis , Sample 2,2 L-menthol Organism Control 14 days 28 days Pass/Fail Control Count Test Count % Increase/ Test Count % Increase/
(cfu/mL) decrease in cfu (cfu/mL) decrease in cfu Pseudomonas 12 i0 0 100% decrease 0 100% decrease Pass aeru inosa Staphylococcus 1.4 x 106 0 100% decrease 0 100% decrease Pass aureus Escherichia coli 7.1 x 105 0 100% decrease 0 100% decrease Pass a Candida albicans 2.1 x 106 0 100% decrease 0 100% decrease Pass =:
Aspergillus 3_2 x 10 0 100% decrease 0 100% decrease Pass :#
brasiliensis #
'I
õet BAT: P10018254; 81883115- DYC: P115645PCT
ci 0, Sarni;le 2.3 ti*
ar ...4 X
CD
.0 :gc 0 Organism Control 14 days 28 days Pass/Fail E4-==i, ID Control Count Test Count % Increase/ Test Count % Increase/ =
iir ISr.
x cfuimL decrease in cfu cfu/mL
decrease in cfu aN
'cak 0 Pseudomonas 1.4 x10 0 100% decrease 0 100% decrease Pass 4*, CD
R* aeru inosa 0_ N) Staphylococcus 2.0 x 106 0 100% decrease 0 100% decrease Pass ry aureus f?
Escherichia coil 2.0 x 106 0 100% decrease 0 100% decrease Pass '8 Candida albicans 1.7 x 106 0 100% decrease 0 100% decrease Pass Aspergillus 4.9 x 105 0 100% decrease 0 100% decrease Pass brasiliensis Each of samples 2:1*2 2 and2Zwere found to significantly inhibit microbial growth. In respect of the majority of samples tested a 100%
INI 5 decrease in was observed.
a #
.8:
..,,,, Various modifications and variations of the present invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention.
Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in chemistry or related fields are intended to be within the scope of the following claims.
Claims (35)
1. An aerosolisable formulation comprising (i) water in an amount of at least 20 wt.% based on the aerosolisable formulation;
(ii) nicotine;
(iii) an acid which is at least partially water soluble present in an amount of from 0.08 to 6 wt%
based on the aerosolisable formulation; and (iv) one or more cyclodextrins;
wherein at least 5 wt% of the nicotine present in the formulation is in protonated form; and wherein the formulation has a pH of from 4 to 6.
(ii) nicotine;
(iii) an acid which is at least partially water soluble present in an amount of from 0.08 to 6 wt%
based on the aerosolisable formulation; and (iv) one or more cyclodextrins;
wherein at least 5 wt% of the nicotine present in the formulation is in protonated form; and wherein the formulation has a pH of from 4 to 6.
2. The aerosolisable formulation according to claim 1 wherein the water is present in an amount of at least 40 wt.% based on the aerosolisable formulation.
3. The aerosolisable formulation according to claim 1 or 2 wherein the water is present in an amount of at least 60 wt.% based on the aerosolisable formulation.
4 The aerosolisable formulation according to any one of claims 1 to 3 wherein the water is present in an amount of at least 80 wt.% based on the aerosolisable formulation.
The aerosolisable formulation according to any one of claims 1 to 4 wherein the water is present in an amount of at least 90 wt.% based on the aerosolisable formulation.
6 The aerosolisable formulation according to any one of claims 1 to 5 wherein the nicotine is present in an amount of no greater than 0.2wt.% based on the aerosolisable formulation.
7. The aerosolisable formulation according to claim 6 wherein the nicotine is present in an amount of from 0.01 to 0.1wt.% based on the aerosolisable formulation.
8. The aerosolisable formulation according to any one of claims 1 to 7 wherein the acid has a solubility in water of at least 100 g/100 mL at 20 C.
9. The aerosolisable formulation according to any one of claims 1 to 8 wherein at least 20 wt% of the nicotine present in the formulation is in protonated form.
Date Recue/Date Received 2023-06-19
Date Recue/Date Received 2023-06-19
10. The aerosolisable formulation according to any one of claims 1 to 8 wherein at least 30 wt% of the nicotine present in the formulation is in protonated form.
11. The aerosolisable formulation according to any one of claims 1 to 10 wherein the molar ratio of acid to nicotine is from 3:1 to 1:3.
12. The aerosolisable formulation according to any one of claims 1 to 11 wherein the molar ratio of acid to nicotine is from 2:1 to 1:2.
13. The aerosolisable formulation according to any one of claims 1 to 12 wherein the molar ratio of acid to nicotine is from 1.2:1 to 1:1.2.
14. The aerosolisable formulation according to any one of claims 1 to 10 wherein the acid is a carboxylic acid.
15. The aerosolisable formulation according to any one of claims 1 to 10 wherein the acid is selected from the group consisting of citric acid, maleic acid, lactic acid, levulinic acid, benzoic acid, sorbic acid, acetic acid and mixtures thereof.
16. The aerosolisable formulation according to any one of claims 1 to 15 wherein the acid is at least citric acid.
17. The aerosolisable formulation according to any one of claims 1 to 16 further comprising one or more flavours.
18. The aerosolisable formulation according to claim 17 wherein the one or more flavours are selected from the group consisting of (4-(para-)methoxyphenyl)-2-butanone, vanillin, y-undecalactone, menthone, 5-propenyl guaethol, menthol, para-mentha-8-thiol-3-one and mixtures thereof.
19. The aerosolisable formulation according to claim 18 wherein the flavour is at least menthol.
Date Recue/Date Received 2023-06-19
Date Recue/Date Received 2023-06-19
20. The aerosol isable formulation according to any one of claims 17 to 19 wherein the one or more flavours are present in a total amount of from 0.01 to lwt.% based on the aerosolisable formulation.
21. The aerosolisable formulation according to any one of claims 1 to 16 consisting essentially of (i) water;
(ii) nicotine;
(iii) the acid; and (iv) one or more cyclodextrins.
(ii) nicotine;
(iii) the acid; and (iv) one or more cyclodextrins.
22. The aerosolisable formulation according to any one of claims 1 to 20 consisting essentially of (i) water;
(ii) nicotine;
(iii) the acid;
(iv) one or more flavours; and (v) one or more cyclodextrins.
(ii) nicotine;
(iii) the acid;
(iv) one or more flavours; and (v) one or more cyclodextrins.
23. A process for forming an aerosol, the process comprising aerosolising an aerosolisable formulation comprising (i) water in an amount of at least 20 wt.% based on the aerosolisable formulation;
(ii) nicotine;
(iii) an acid which is at least partially water soluble present in an amount of from 0.08 to 6 wt%
based on the aerosolisable formulation; and (iv) one or more cyclodextrins;
wherein at least 5 wt% of the nicotine present in the formulation is in protonated form; and wherein the formulation has a pH of from 4 to 6.
(ii) nicotine;
(iii) an acid which is at least partially water soluble present in an amount of from 0.08 to 6 wt%
based on the aerosolisable formulation; and (iv) one or more cyclodextrins;
wherein at least 5 wt% of the nicotine present in the formulation is in protonated form; and wherein the formulation has a pH of from 4 to 6.
24. The process according to claim 23 wherein the aerosolisable formulation is an aerosolisable formulation as defined in any one of claims 2 to 22.
25. The process according to claim 23 or 24 wherein the aerosol is formed by a process performed at a temperature below 50 C.
Date Recue/Date Received 2023-06-19
Date Recue/Date Received 2023-06-19
26. The process according to any one of claims 23 to 25 wherein the aerosol is formed by applying ultrasonic energy to the aerosolisable formulation.
27. A contained aerosolisable formulation comprising (a) a container; and (b) an aerosolisable formulation, comprising (i) water in an amount of at least 20 wt.% based on the aerosolisable formulation;
(ii) nicotine; and (iii) an acid which is at least partially water soluble present in an amount of from 0.08 to 6 wt% based on the aerosolisable formulation; and (iv) one or more cyclodextrins wherein at least 5 wt% of the nicotine present in the formulation is in protonated form; and wherein the formulation has a pH of from 4 to 6.
(ii) nicotine; and (iii) an acid which is at least partially water soluble present in an amount of from 0.08 to 6 wt% based on the aerosolisable formulation; and (iv) one or more cyclodextrins wherein at least 5 wt% of the nicotine present in the formulation is in protonated form; and wherein the formulation has a pH of from 4 to 6.
28. The contained aerosolisable formulation according to claim 27 wherein the aerosolisable formulation is the aerosolisable formulation as defined in any one of claims 2 to 20.
29. The contained aerosolisable formulation according to claim 27 or 28 wherein the container is configured for engagement with an electronic aerosol provision system.
30. An electronic aerosol provision system comprising:
(a) an aerosoliser for aerosolising formulation for inhalation by a user of the electronic aerosol provision system;
(b) a power supply comprising a cell or battery for supplying power to the aerosoliser (c) an aerosolisable formulation , comprising (i) water in an amount of at least 20 wt.% based on the aerosolisable formulation;
(ii) nicotine; and (iii) an acid which is at least partially water soluble present in an amount of from 0.08 to 6 wt% based on the aerosolisable formulation; and (iv) one or more cyclodextrins;
wherein at least 5 wt% of the nicotine present in the formulation is in protonated form; and wherein the formulation has a pH of from 4 to 6.
Date Recue/Date Received 2023-06-19
(a) an aerosoliser for aerosolising formulation for inhalation by a user of the electronic aerosol provision system;
(b) a power supply comprising a cell or battery for supplying power to the aerosoliser (c) an aerosolisable formulation , comprising (i) water in an amount of at least 20 wt.% based on the aerosolisable formulation;
(ii) nicotine; and (iii) an acid which is at least partially water soluble present in an amount of from 0.08 to 6 wt% based on the aerosolisable formulation; and (iv) one or more cyclodextrins;
wherein at least 5 wt% of the nicotine present in the formulation is in protonated form; and wherein the formulation has a pH of from 4 to 6.
Date Recue/Date Received 2023-06-19
31. The electronic aerosol provision system according to claim 30 wherein the aerosolisable formulation is the aerosolisable formulation as defined in any one of claims 2 to 20.
32. A process for improving the sensory properties of an aerosolised nicotine formulation, the process comprising the steps of (a) providing an aerosolisable material comprising (i) water in an amount of at least 20 wt.% based on the aerosolisable material and (ii) nicotine;
(b) incorporating into the aerosolisable material an acid which is at least partially water soluble in an amount of from 0.08 to 6 wt% based on the aerosolisable material and one or more cyclodextrins;
wherein at least 5 wt% of the nicotine present in the formulation is in protonated form; and wherein the formulation has a pH of from 4 to 6.
(b) incorporating into the aerosolisable material an acid which is at least partially water soluble in an amount of from 0.08 to 6 wt% based on the aerosolisable material and one or more cyclodextrins;
wherein at least 5 wt% of the nicotine present in the formulation is in protonated form; and wherein the formulation has a pH of from 4 to 6.
33. A process for improving the storage stability of an aerosolised nicotine formulation, the process comprising the steps of (a) providing an aerosolisable material comprising (i) water in an amount of at least 20 wt.% based on the aerosolisable material and (ii) nicotine;
(b) incorporating into the aerosolisable material an acid which is at least partially water soluble in an amount of from 0.08 to 6 wt% based on the aerosolisable material and one or more cyclodextrins;
wherein at least 5 wt% of the nicotine present in the formulation is in protonated form; and wherein the formulation has a pH of from 4 to 6.
(b) incorporating into the aerosolisable material an acid which is at least partially water soluble in an amount of from 0.08 to 6 wt% based on the aerosolisable material and one or more cyclodextrins;
wherein at least 5 wt% of the nicotine present in the formulation is in protonated form; and wherein the formulation has a pH of from 4 to 6.
34. Use of one or more acids for improving sensory properties of an aerosolised nicotine formulation, wherein the nicotine formulation comprises (i) water in an amount of at least 20 wt.% based on the aerosolisable formulation;
(ii) nicotine;
(iii) an acid which is at least partially water soluble present in an amount of from 0.08 to 6 wt% based on the formulation; and (iv) one or more cyclodextrins; and wherein at least 5 wt% of the nicotine present in the formulation is in protonated form; and wherein the formulation has a pH of from 4 to 6.
(ii) nicotine;
(iii) an acid which is at least partially water soluble present in an amount of from 0.08 to 6 wt% based on the formulation; and (iv) one or more cyclodextrins; and wherein at least 5 wt% of the nicotine present in the formulation is in protonated form; and wherein the formulation has a pH of from 4 to 6.
35. Use of one or more acids for improving storage stability of an aerosolised nicotine Date Recue/Date Received 2023-06-19 formulation, wherein the nicotine formulation comprises (i) water in an amount of at least 20 wt.% based on the aerosolisable formulation;
(ii) nicotine;
(iii) an acid which is at least partially water soluble present in an amount of from 0.08 to 6 wt% based on the formulation; and (iv) one or more cyclodextrins;
wherein at least 5 wt% of the nicotine present in the formulation is in protonated form; and wherein the formulation has a pH of from 4 to 6.
Date Recue/Date Received 2023-06-19
(ii) nicotine;
(iii) an acid which is at least partially water soluble present in an amount of from 0.08 to 6 wt% based on the formulation; and (iv) one or more cyclodextrins;
wherein at least 5 wt% of the nicotine present in the formulation is in protonated form; and wherein the formulation has a pH of from 4 to 6.
Date Recue/Date Received 2023-06-19
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1817867.3A GB201817867D0 (en) | 2018-11-01 | 2018-11-01 | Aerosolisable formulation |
GB1817867.3 | 2018-11-01 | ||
PCT/GB2019/053086 WO2020089633A1 (en) | 2018-11-01 | 2019-10-31 | Aerosolisable formulation |
Publications (2)
Publication Number | Publication Date |
---|---|
CA3118005A1 CA3118005A1 (en) | 2020-05-07 |
CA3118005C true CA3118005C (en) | 2024-03-26 |
Family
ID=64655382
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3118005A Active CA3118005C (en) | 2018-11-01 | 2019-10-31 | Aerosolisable formulation |
Country Status (13)
Country | Link |
---|---|
US (1) | US20230270154A1 (en) |
EP (1) | EP3873241A1 (en) |
JP (2) | JP2022506073A (en) |
KR (1) | KR20210074307A (en) |
CN (1) | CN113260261A (en) |
AU (1) | AU2019371078B2 (en) |
BR (1) | BR112021008570A2 (en) |
CA (1) | CA3118005C (en) |
GB (1) | GB201817867D0 (en) |
IL (1) | IL282617A (en) |
MX (1) | MX2021005164A (en) |
UA (1) | UA127838C2 (en) |
WO (1) | WO2020089633A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11771132B2 (en) | 2020-08-27 | 2023-10-03 | Rai Strategic Holdings, Inc. | Atomization nozzle for aerosol delivery device |
GB202013489D0 (en) | 2020-08-27 | 2020-10-14 | Nicoventures Holdings Ltd | Consumable |
US11771136B2 (en) | 2020-09-28 | 2023-10-03 | Rai Strategic Holdings, Inc. | Aerosol delivery device |
CN114983001A (en) * | 2021-03-02 | 2022-09-02 | 深圳雾灵科技有限公司 | Additive for tobacco products, preparation method and application thereof |
CN113940440A (en) * | 2021-09-30 | 2022-01-18 | 深圳市真味生物科技有限公司 | Electronic atomized liquid with efficient transmission |
WO2023214678A1 (en) * | 2022-05-04 | 2023-11-09 | 주식회사 케이티앤지 | Aerosol generation product and aerosol generation system |
KR20230166197A (en) * | 2022-05-30 | 2023-12-07 | 주식회사 케이티앤지 | Aerosol generating article and aerosol generating system |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0201669D0 (en) * | 2002-06-03 | 2002-06-03 | Pharmacia Ab | New formulation and use thereof |
US7767698B2 (en) * | 2002-06-03 | 2010-08-03 | Mcneil Ab | Formulation and use thereof |
SE536491C2 (en) * | 2012-03-26 | 2013-12-27 | Bionicotine Ab | Bag containing nicotine and a chewing gum composition |
GB201215273D0 (en) * | 2012-08-28 | 2012-10-10 | Kind Consumer Ltd | Nicotine composition |
KR20230013165A (en) * | 2013-05-06 | 2023-01-26 | 쥴 랩스, 인크. | Nicotine salt formulations for aerosol devices and methods thereof |
CA2932464C (en) * | 2013-12-05 | 2023-01-03 | Pax Labs, Inc. | Nicotine liquid formulations for aerosol devices and methods thereof |
TWI664918B (en) * | 2014-05-21 | 2019-07-11 | 瑞士商菲利浦莫里斯製品股份有限公司 | Inductively heatable tobacco product |
GB201413835D0 (en) * | 2014-08-05 | 2014-09-17 | Nicoventures Holdings Ltd | Electronic vapour provision system |
GB2535427A (en) * | 2014-11-07 | 2016-08-24 | Nicoventures Holdings Ltd | Solution |
GB201508671D0 (en) * | 2015-05-20 | 2015-07-01 | British American Tobacco Co | Aerosol generating material and devices including the same |
US10327472B2 (en) * | 2015-09-25 | 2019-06-25 | Altria Client Services Llc | Pre-vaporization formulation for controlling acidity in an e-vaping device |
DE102015117811A1 (en) * | 2015-10-20 | 2017-04-20 | Chv Pharma Gmbh & Co. Kg | Inhaler and active ingredient-containing preparation for an inhaler |
US20180199618A1 (en) * | 2016-09-27 | 2018-07-19 | Bond Street Manufacturing Llc | Vaporizable Tobacco Wax Compositions and Container thereof |
EP3574902A1 (en) * | 2018-06-01 | 2019-12-04 | Yatzz Limited | Nicotine formulation and mode of delivery |
-
2018
- 2018-11-01 GB GBGB1817867.3A patent/GB201817867D0/en not_active Ceased
-
2019
- 2019-10-31 AU AU2019371078A patent/AU2019371078B2/en active Active
- 2019-10-31 WO PCT/GB2019/053086 patent/WO2020089633A1/en unknown
- 2019-10-31 KR KR1020217012898A patent/KR20210074307A/en not_active Application Discontinuation
- 2019-10-31 CN CN201980087212.9A patent/CN113260261A/en active Pending
- 2019-10-31 MX MX2021005164A patent/MX2021005164A/en unknown
- 2019-10-31 UA UAA202102266A patent/UA127838C2/en unknown
- 2019-10-31 CA CA3118005A patent/CA3118005C/en active Active
- 2019-10-31 US US17/290,652 patent/US20230270154A1/en active Pending
- 2019-10-31 BR BR112021008570-0A patent/BR112021008570A2/en unknown
- 2019-10-31 EP EP19798361.2A patent/EP3873241A1/en active Pending
- 2019-10-31 JP JP2021523231A patent/JP2022506073A/en active Pending
-
2021
- 2021-04-25 IL IL282617A patent/IL282617A/en unknown
-
2023
- 2023-06-20 JP JP2023101027A patent/JP2023120357A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2020089633A1 (en) | 2020-05-07 |
US20230270154A1 (en) | 2023-08-31 |
AU2019371078B2 (en) | 2022-07-14 |
CN113260261A (en) | 2021-08-13 |
CA3118005A1 (en) | 2020-05-07 |
KR20210074307A (en) | 2021-06-21 |
UA127838C2 (en) | 2024-01-17 |
BR112021008570A2 (en) | 2021-08-03 |
JP2023120357A (en) | 2023-08-29 |
IL282617A (en) | 2021-06-30 |
GB201817867D0 (en) | 2018-12-19 |
EP3873241A1 (en) | 2021-09-08 |
AU2019371078A1 (en) | 2021-05-27 |
JP2022506073A (en) | 2022-01-17 |
MX2021005164A (en) | 2021-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA3118005C (en) | Aerosolisable formulation | |
AU2019373767B2 (en) | Gel and crystalline powder | |
AU2019371079B2 (en) | Aerosolisable formulation | |
AU2019373768B2 (en) | Aerosolisable formulation | |
CA3117820C (en) | Aerosolisable formulation | |
AU2019372222B2 (en) | Aerosolisable formulation | |
RU2806059C2 (en) | Aerosol creating composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20210428 |
|
EEER | Examination request |
Effective date: 20210428 |
|
EEER | Examination request |
Effective date: 20210428 |
|
EEER | Examination request |
Effective date: 20210428 |
|
EEER | Examination request |
Effective date: 20210428 |
|
EEER | Examination request |
Effective date: 20210428 |
|
EEER | Examination request |
Effective date: 20210428 |
|
EEER | Examination request |
Effective date: 20210428 |
|
EEER | Examination request |
Effective date: 20210428 |
|
EEER | Examination request |
Effective date: 20210428 |